DLL3 targeting antibodies and uses thereof

By developing antibodies or antigen binding fragments against DLL3, the problem of treatment of high-grade lung neuroendocrine tumors in the prior art has been solved, and targeted treatment of small-cell lung cancer and large-cell neuroendocrine cancer has been achieved, which has significantly improved the therapeutic effect .

CN119080930APending Publication Date: 2024-12-06MEMORIAL SLOAN KETTERING CANCER CENT +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411174923.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-07-11
Filing Date
2020-07-08
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing treatments are difficult to effectively target high-level and poor prognostic pulmonary neuroendocrine tumors, especially small-cell lung cancer and large-cell neuroendocrine cancer, and there is a lack of specific targeted therapeutic methods for these tumors.

Method used

Antibodies or antigen-binding fragments thereof targeting delta-like protein 3 (DLL3) have been developed to achieve toxic payload delivery and targeted therapy for tumor cells through specific binding and internalization of DLL3.

Benefits of technology

This method can significantly improve the treatment effect of DLL3-related cancers such as small-cell lung cancer and large-cell neuroendocrine cancer, and provides a new targeted treatment method, which enhances the therapeutic potential of these tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080930A_ABST
    Figure CN119080930A_ABST
Patent Text Reader

Abstract

The present invention relates generally to immunoglobulin related compositions (e.g., antibodies or antigen-binding fragments thereof) capable of binding to delta-like protein 3 (DLL3). The antibodies of the technology of the invention are useful in methods of detecting and treating DLL3-related cancers in a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

This invention application is a divisional application based on an invention patent application with an application date of July 8, 2020, application number 202080062231.9 (international application number PCT / US2020 / 041282) and name “DLL3 targeting antibodies and uses thereof”. CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 872,915, filed on July 11, 2019, the entire contents of which are incorporated herein by reference. Technical Field

[0002] The present invention generally relates to the preparation of immunoglobulin-related compositions (e.g., antibodies or antigen-binding fragments thereof) that specifically bind to delta-like protein 3 (DLL3) and the use of the immunoglobulin-related compositions. In particular, the present invention relates to the preparation of DLL3-binding antibodies and their use in the detection and treatment of DLL3-related cancers, including small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinoma, and large cell neuroendocrine carcinoma (LCNEC). Government Support Statement

[0003] This invention was made with U.S. Government support under CA213448 awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention. Background Art

[0004] The following description of the technical background of the present invention is only provided to help understand the present invention, and it is not admitted that the description describes or constitutes the prior art for the present invention.

[0005] Pulmonary neuroendocrine tumors (Lu-NETs) encompass a heterogeneous family of tumors, divided into four histological variants, namely typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). Both SCLC and pulmonary LCNEC are high-grade and poorly prognostic tumors, with a higher incidence in smokers. Similar to SCLC, pulmonary LCNEC exhibits biologically aggressive behavior. The survival curves of pulmonary LCNEC and SCLC overlap stage by stage, and in addition, the survival rate is lower than that of other NSCLCs. Even in patients with potentially resectable stage I lung cancer, whose 5-year survival rate ranges from 27% to 67%, the prognosis is poor. See Iyoda A. et al., J Thorac Cardiovasc Surg. 138: 446–453 (2009). Summary of the invention

[0006] In one aspect, the present disclosure provides an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain immunoglobulin variable domain (V H ) and light chain immunoglobulin variable domain (V L ), wherein (a) V H Contains V selected from the following H -CDR1 sequence, V H -CDR2 sequence and V H - CDR3 sequences: (i) SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively; (ii) SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15, respectively; (iii) SEQ ID NO: 23, SEQ ID NO: 24 and SEQ ID NO: 25, respectively; and (iv) SEQ ID NO: 33, SEQ ID NO: 34 and SEQ ID NO: 35, respectively; and / or (b) the V L Contains V selected from the following L -CDR1 sequence, V L -CDR2 sequence and V L - CDR3 sequences: (i) SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively; (ii) SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, respectively; (iii) SEQ ID NO: 28, SEQ ID NO: 29 and SEQ ID NO: 30, respectively; and (iv) SEQ ID NO: 38, SEQ ID NO: 39 and SEQ ID NO: 40, respectively. In certain embodiments, the antibody or antigen-binding fragment comprises one or more of the following features: (a) a light chain immunoglobulin variable domain sequence that is at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the light chain immunoglobulin variable domain sequence present in any one of SEQ ID NO:7, 17, 27 or 37; and / or (b) a heavy chain immunoglobulin variable domain sequence that is at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the heavy chain immunoglobulin variable domain sequence present in any one of SEQ ID NO:2, 12, 22 or 32.

[0007] In another aspect, the disclosure provides a heavy chain immunoglobulin variable domain (V H ) and light chain immunoglobulin variable domain (V L ) or its antigen-binding fragment, wherein: (a) said VH comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 12, SEQ ID NO: 22 and SEQ ID NO: 32; and / or (b) V L comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, and SEQ ID NO: 37. In some embodiments of the antibody or antigen-binding fragment, the V H Amino acid sequence and the V L The amino acid sequence is selected from: SEQ ID NO: 2 and SEQ ID NO: 7 (7-I1-B), respectively; SEQ ID NO: 12 and SEQ ID NO: 17 (2-C8-A), respectively; SEQ ID NO: 22 and SEQ ID NO: 27 (10-O18-A), respectively; and SEQ ID NO: 32 and SEQ ID NO: 37 (6-G23-F), respectively.

[0008] Additionally or alternatively, in certain embodiments, the antibodies or antigen-binding fragments of the present technology bind to an epitope present in a mammalian DLL3 polypeptide. The epitope can be a conformational epitope or a non-conformational epitope. Additionally or alternatively, in some embodiments, the mammalian DLL3 polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, and SEQ ID NO:54. In some embodiments, the mammalian DLL3 polypeptide has an amino acid sequence comprising amino acid residues 27-492 of SEQ ID NO:50 or SEQ ID NO:51 (e.g., the mammalian DLL3 polypeptide can comprise the extracellular domain of human DLL3). Additionally or alternatively, in some embodiments, when the antibody or antigen-binding fragment binds to a DLL3 polypeptide expressed on the surface of a cell (e.g., the surface of a tumor cell), the antibody or antigen-binding fragment undergoes intracellular internalization.

[0009] Additionally or alternatively, in any embodiment disclosed herein, the antibody or antigen-binding fragment further comprises an Fc domain of an isotype selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgM, IgD, and IgE. Additionally or alternatively, in any embodiment disclosed herein, the antigen-binding fragment is selected from the group consisting of Fab, F(ab'), 2 , Fab', scF v and F vAdditionally or alternatively, in some embodiments, the antibody or antigen-binding fragment of the present technology is a monoclonal antibody, a chimeric antibody, a humanized antibody, or a bispecific antibody.

[0010] In one aspect, the disclosure provides a recombinant nucleic acid sequence encoding any of the antibodies or antigen-binding fragments described herein. In some embodiments, the recombinant nucleic acid sequence is selected from the group consisting of: SEQ ID NO: 1, 6, 11, 16, 21, 26, 31 and 36.

[0011] In another aspect, the present disclosure provides a host cell or a vector comprising any of the recombinant nucleic acid sequences disclosed herein.

[0012] In one aspect, the present disclosure provides a composition comprising an antibody or antigen-binding fragment of the present technology and a pharmaceutically acceptable carrier, wherein the antibody or antigen-binding fragment is optionally conjugated to an agent selected from the following: an isotope, a dye, a chromagen, a contrast agent, a drug, a toxin, a cytokine, an enzyme, an enzyme inhibitor, a hormone, a hormone antagonist, a growth factor, a radionuclide, a metal, a liposome, a nanoparticle, RNA, DNA or any combination thereof.

[0013] In one aspect, the present disclosure provides a method for treating a DLL3-related cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment of the present technology, wherein the antibody or antigen-binding fragment is conjugated to at least one additional therapeutic agent. Examples of such additional therapeutic agents include, but are not limited to, isotopes, drugs, toxins, cytokines, enzymes, enzyme inhibitors, hormones, hormone antagonists, growth factors, radionuclides, metals, liposomes, nanoparticles, RNA, DNA, or any combination thereof. The DLL3-related cancer can be small cell lung cancer, large cell neuroendocrine cancer, pulmonary neuroendocrine cancer, extrapulmonary neuroendocrine cancer, or melanoma.

[0014] In another aspect, the present disclosure provides a method for detecting the expression level of DLL3 protein in a biological sample, the method comprising contacting the biological sample with the antibody or antigen-binding fragment described herein, wherein the antibody or antigen-binding fragment is conjugated to a detectable label; and detecting a signal generated by the detectable label in the biological sample.

[0015] Also disclosed herein is a kit for detecting and / or treating DLL3-related cancers, the kit comprising at least one immunoglobulin-related composition of the present technology (e.g., any antibody or antigen-binding fragment described herein) or a functional variant thereof (e.g., a substitution variant) and instructions for use. In certain embodiments, the immunoglobulin-related composition is coupled to one or more detectable labels. In one embodiment, the one or more detectable labels include a radioactive label, a fluorescent label, or a chromogenic label.

[0016] Additionally or alternatively, in some embodiments, the kit further comprises a secondary antibody that specifically binds to the anti-DLL3 immunoglobulin-related composition described herein. In some embodiments, the secondary antibody is conjugated to at least one detectable label selected from a radioactive label, a fluorescent label, or a chromogenic label. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 Results of a Fab ZAP assay (a cytotoxicity-based internalization assay) performed to determine internalization of DLL3 by the indicated antibodies are shown. Reference DLL3 monoclonal antibody SC16 was used as a positive control. See WO 2015127407. All anti-DLL3 antibodies tested exhibited comparable killing activity to the reference monoclonal antibody. A hook effect was observed at higher concentrations of anti-DLL3 antibodies as free anti-DLL3 competed with cell-bound anti-DLL3 for the Fab ZAP.

[0018] Figure 2A-2D Antibody 7-I1-B ( Figure 2A )、6-G23-F( Figure 2B )、10-O18-A( Figure 2C ) and 2-C8-A( Figure 2D ) as measured via Octet HTX at 25°C using PBS 0.1% BSA 0.02% Tween 20 as binding buffer and 10 mM glycine (pH 1.7) as regeneration buffer. Monoclonal antibodies (5 μg / mL each) were loaded onto the anti-mouse Fc sensor, and the loaded sensor was immersed in the indicated dilutions of recombinant human DLL3 protein (amino acids Ala27-Ala479, catalog number 9749-DL, R&D Systems) with 7 serial 1:3 dilutions at a starting concentration of 200 nM. For each DLL3 dilution, the actual measured values ​​and the curve fit are shown.

[0019] Figure 2E The dissociation constants (K) of the four monoclonal antibodies described herein (6-G23-F, 2-C8-A, 7-I1-B, and 10-018-A) are shown. D) value, which is used as Figure 2A-2D Binding curves are shown and were calculated using a monovalent (1:1) binding model.

[0020] Figure 3A The V of antibody 7-I1-B is shown. H The nucleotide sequence and amino acid sequence of the domain are represented by SEQ ID NO: 1 and SEQ ID NO: 2, respectively. H CDR1 (SEQ ID NO: 3) is shown in bold font, V H CDR2 (SEQ ID NO: 4) is underlined, and V H CDR3 (SEQ ID NO:5) is indicated in italic, underlined font.

[0021] Figure 3B The V of antibody 7-I1-B is shown. L The nucleotide sequence and amino acid sequence of the domain are represented by SEQ ID NO: 6 and SEQ ID NO: 7, respectively. L CDR1 (SEQ ID NO: 8) is shown in bold, V L CDR2 (SEQ ID NO: 9) is underlined, and V L CDR3 (SEQ ID NO: 10) is indicated in italic, underlined font.

[0022] Figure 4A The V of antibody 2-C8-A is shown. H The nucleotide sequence and amino acid sequence of the domain are represented by SEQ ID NO: 11 and SEQ ID NO: 12, respectively. H CDR1 (SEQ ID NO: 13) is shown in bold font, V H CDR2 (SEQ ID NO: 14) is underlined, and V H CDR3 (SEQ ID NO: 15) is indicated in italic, underlined font.

[0023] Figure 4B The V of antibody 2-C8-A is shown. L The nucleotide sequence and amino acid sequence of the domain are represented by SEQ ID NO: 16 and SEQ ID NO: 17, respectively. L CDR1 (SEQ ID NO: 18) is shown in bold, V L CDR2 (SEQ ID NO: 19) is underlined, and V L CDR3 (SEQ ID NO:20) is indicated in italic, underlined font.

[0024] Figure 5A The V of antibody 10-O18-A is shown. H The nucleotide sequence and amino acid sequence of the domain are represented by SEQ ID NO: 21 and SEQ ID NO: 22, respectively. H CDR1 (SEQ ID NO: 23) is shown in bold font, V H CDR2 (SEQ ID NO: 24) is underlined, and V H CDR3 (SEQ ID NO:25) is indicated in italic, underlined font.

[0025] Figure 5B The V of antibody 10-O18-A is shown. L The nucleotide sequence and amino acid sequence of the V domain are represented by SEQ ID NO: 26 and SEQ ID NO: 27, respectively. L CDR1 (SEQ ID NO: 28) is shown in bold, V L CDR2 (SEQ ID NO: 29) is underlined, and V L CDR3 (SEQ ID NO: 30) is indicated in italic, underlined font.

[0026] Fig. 6A The V of antibody 6-G23-F is shown. H The nucleotide sequence and amino acid sequence of the domain are represented by SEQ ID NO: 31 and SEQ ID NO: 32, respectively. H CDR1 (SEQ ID NO: 33) is shown in bold font, V H CDR2 (SEQ ID NO: 34) is underlined, and V H CDR3 (SEQ ID NO:35) is indicated in italic, underlined font.

[0027] Figure 6B The V of antibody 6-G23-F is shown. L The nucleotide sequence and amino acid sequence of the domain are represented by SEQ ID NO: 36 and SEQ ID NO: 37, respectively. L CDR1 (SEQ ID NO: 38) is shown in bold, V L CDR2 (SEQ ID NO: 39) is underlined, and V L CDR3 (SEQ ID NO:40) is indicated in italic, underlined font.

[0028] Figure 7It was shown that 6-G23-F, 10-018-A, and 2-C8-A monoclonal antibodies (mAbs) selectively bind to DLL3, but not to DLL1 or DLL4. 7-I1-B mAb binds to both DLL3 and DLL4, but not DLL1.

[0029] Fig. 8A The nucleotide sequence and amino acid sequence of Homo sapiens delta-like canonical Notch ligand 3 (DLL3) isoform 1 are shown as SEQ ID NO:55 and SEQ ID NO:50, respectively. Figure 8B The nucleotide sequence and amino acid sequence of Homo sapiens delta-like canonical Notch ligand 3 (DLL3) isoform 2 are shown as SEQ ID NO:56 and SEQ ID NO:51, respectively. DETAILED DESCRIPTION

[0030] It should be appreciated that certain aspects, modes, embodiments, variations, and features of the present technology are described at various levels of detail in order to provide a substantial understanding of the present technology.

[0031] In practicing the methods of the present invention, many conventional techniques in molecular biology, protein biochemistry, cell biology, immunology, microbiology, and recombinant DNA are used. See, for example, Sambrook and Russell, eds. (2001) Molecular Cloning: A Laboratory Manual, 3rd ed.; Ausubel et al., eds. (2007) Current Protocols in Molecular Biology; Methods in Enzymology (Academic Press, Inc., NY); MacPherson et al. (1991) PCR 1: A Practical Approach (IRL Press at Oxford University Press); MacPherson et al. (1995) PCR 2: A Practical Approach; Harlow and Lane, eds. (1999) Antibodies, A Laboratory Manual; Freshney (2005) Culture of Animal Cells: A Manual of Basic Technique, 5th edition; Gait, ed. (1984) Oligonucleotide Synthesis; U.S. Pat. No. 4,683,195; Hames and Higgins, eds. (1984) Nucleic Acid Hybridization; Anderson (1999) Nucleic Acid Hybridization; Hames and Higgins, eds. (1984) Transcription and Translation; Immobilized Cells and Enzymes (IRL Press (1986)); Perbal (1984) A Practical Guide to Molecular Cloning; Miller and Calos, ed. (1987) Gene Transfer Vectors for Mammalian Cells (Cold Spring Harbor Laboratory); Makrides, ed. (2003) Gene Transfer and Expression in Mammalian Cells; Mayer and Walker, ed. (1987) Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); and Herzenberg et al., ed. (1996) Weir's Handbook of Experimental Immunology. Methods for detecting and measuring the level of polypeptide gene expression products (i.e., gene translation levels) are well known in the art and include the use of polypeptide detection methods, such as antibody detection and quantification techniques. (See also, Strachan and Read, Human Molecular Genetics, 2nd Edition (John Wiley and Sons, Inc., NY, 1999)). .

[0032] DLL3 is selectively expressed in high-grade pulmonary neuroendocrine tumors, including SCLC and LCNEC. Increased expression of DLL3 was observed in xenograft tumors derived from SCLC and LCNEC patients and was also confirmed in primary tumors. See Saunders et al., Sci Translational Medicine 7(302):302ra136(2015). Increased expression of DLL3 was also observed in extrapulmonary neuroendocrine cancers, including prostate neuroendocrine cancer (Puca et al., Sci Transl Med 11(484):pii:eaav0891(2019)). Although DLL3 is expressed on the surface of such tumor cells, it is not expressed in normal tissues. The present disclosure provides immunoglobulin-related compositions (e.g., antibodies or antigen-binding fragments thereof) that are internalized when bound to DLL3 on tumor cells and can therefore be used to deliver toxic payloads to these tumor cells. The immunoglobulin-related compositions of the present technology can be used in methods for detecting or treating DLL3-related cancers in subjects in need thereof. Thus, various aspects of the methods of the invention relate to the preparation, characterization and manipulation of anti-DLL3 antibodies. The immunoglobulin-related compositions of the present technology can be used alone or in combination with additional therapeutic agents for the treatment of cancer. In some embodiments, the immunoglobulin-related compositions are humanized antibodies, chimeric antibodies or bispecific antibodies. definition

[0033] The following provides definitions of certain terms as used in this specification. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs.

[0034] As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. For example, reference to "a cell" includes combinations of two or more cells, and the like. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, analytical chemistry, and nucleic acid chemistry and hybridization described below are those well known and commonly used in the art.

[0035] As used herein, the term "about" with respect to a number is generally deemed to include numbers that fall within 1%, 5%, or 10% in either direction (greater than or less than) of the stated number, unless the context indicates otherwise or it is otherwise obvious (except where such a number is below 0% or above 100% of the possible value).

[0036] As used herein, "administering" an agent or drug to a subject includes any route of introducing or delivering a compound to a subject to perform its intended function. Administration can be by any suitable route, including oral, intranasal, parenteral (intravenous, intramuscular, intraperitoneal or subcutaneous), rectal, intrathecal, intratumoral, or topical. Administration includes self-administration and administration by another person.

[0037] "Adjuvant" refers to one or more substances that cause immune system stimulation. In this case, the adjuvant is used to enhance the immune response to one or more vaccine antigens or antibodies. The adjuvant can be administered to the subject before, in combination with, or after the administration of the vaccine. Examples of chemical compounds used as adjuvants include aluminum compounds, oils, block polymers, immunostimulatory complexes, vitamins and minerals (e.g., vitamin E, vitamin A, selenium, and vitamin B12), Quil A (saponin), bacterial and fungal cell wall components (e.g., lipopolysaccharides, lipoproteins, and glycoproteins), hormones, cytokines, and co-stimulatory factors.

[0038] As used herein, the term "amino acid" is used to refer to any organic molecule containing at least one amino group and at least one carboxyl group. Typically, at least one amino group is in the alpha position relative to the carboxyl group. The term "amino acid" includes naturally occurring amino acids and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are amino acids encoded by the genetic code, as well as those amino acids that are later modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds having the same basic chemical structure as naturally occurring amino acids (i.e., α carbon is combined with hydrogen, carboxyl, amino group, and R group), such as homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimetics refer to chemical compounds that have a structure different from the general chemical structure of amino acids, but function in a manner similar to naturally occurring amino acids. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission.

[0039] As used herein, the term "antibody" collectively refers to immunoglobulins or immunoglobulin-like molecules, including, for example, but not limited to, IgA, IgD, IgE, IgG, and IgM, combinations thereof, and similar molecules produced during an immune response in any vertebrate, such as mammals (such as humans, goats, rabbits, and mice), as well as non-mammalian species (such as shark immunoglobulins). As used herein, "antibodies" (including complete immunoglobulins) and "antigen-binding fragments" specifically bind to a target molecule (or a group of highly similar target molecules) while substantially excluding binding to other molecules (e.g., a binding constant for the target molecule is at least 10 greater than a binding constant for other molecules in a biological sample). 3 M -1 , at least 10 4 M -1 or at least 10 5 M -1 The term "antibody" also includes genetically engineered forms such as chimeric antibodies (e.g., humanized murine antibodies), heteroconjugate antibodies (e.g., bispecific antibodies). See also Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, IL); Kuby, J., Immunology, 3rd Edition, WH Freeman & Co., New York, 1997.

[0040] More specifically, an antibody refers to a polypeptide ligand that specifically recognizes and binds to an antigen epitope and contains at least a light chain immunoglobulin variable region or a heavy chain immunoglobulin variable region. Antibodies are composed of heavy chains and light chains, each of which has a variable region, called a heavy chain variable region (V H ) region and light chain variable (V L ) area. H Area and V LThe regions are jointly responsible for binding to the antigen recognized by the antibody. Typically, immunoglobulins have heavy (H) chains and light (L) chains interconnected by disulfide bonds. There are two types of light chains, λ (lambda) and κ (kappa). There are five main heavy chain categories (or isotypes): IgM, IgD, IgG, IgA and IgE, which determine the functional activity of the antibody molecule. Each heavy chain and light chain contains a constant region and a variable region (the region is also referred to as a "domain"). Combined, the heavy chain variable region and the light chain variable region specifically bind to the antigen. The light chain variable region and the heavy chain variable region contain a "framework" region interrupted by three hypervariable regions (also referred to as "complementarity determining regions" or "CDRs"). The scope of the framework region and CDR has been defined (see Kabat et al., Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, 1991, which is hereby incorporated by reference). The Kabat database is currently maintained online. The sequences of the framework regions of different light or heavy chains are relatively conserved within species. The framework region of an antibody (i.e., the combined framework region of the constituent light and heavy chains) predominantly adopts a β-sheet conformation, and the CDR forms a loop connecting the β-sheet structure, and in some cases the loop forms a part of the β-sheet structure. Therefore, the framework region plays a role in forming a scaffold that positions the CDR in the correct orientation through interchain non-covalent interactions.

[0041] The CDRs are primarily responsible for binding to the antigenic epitope. The CDRs of each chain are usually referred to as CDR1, CDR2, and CDR3, are numbered sequentially starting from the N-terminus, and are usually also identified according to the chain in which a particular CDR is located. H CDR3 is located in the variable domain of the heavy chain of the antibody in which it is found, while V L CDR1 is the CDR1 of the variable domain of the light chain of the antibody in which it is found. An antibody that binds to a DLL3 protein will have a specific V H Area and V L Region sequence, thus having a specific CDR sequence. Antibodies with different specificities (i.e., different binding sites for different antigens) have different CDRs. Although CDRs are different between different antibodies, only a limited number of amino acid positions in the CDR are directly involved in antigen binding. These positions in the CDR are called specificity determining residues (SDRs). As used herein, "immunoglobulin-related compositions" refer to antibodies (including monoclonal antibodies, polyclonal antibodies, humanized antibodies, chimeric antibodies, recombinant antibodies, multispecific antibodies, bispecific antibodies, etc.) and antibody fragments. Antibodies or their antigen-binding fragments specifically bind to antigens.

[0042] As used herein, the term "antibody-related polypeptide" refers to an antigen-binding antibody fragment, including a single-chain antibody, which may contain one or more variable regions alone or in combination with all or part of the following polypeptide elements: the hinge region of an antibody molecule, a CH 1 , CH 2 and CH 3 The technology also includes one or more variable regions and hinge regions, CH 1 , CH 2 and CH 3 Any combination of domains. Antibody-related molecules that can be used in this method include, but are not limited to, Fab, Fab' and F(ab') 2 , Fd, single-chain Fv (scFv), single-chain antibody, disulfide-linked Fv (sdFv) and V L or V H Examples include: (i) Fab fragments, i.e., fragments of V L 、V H , C L and CH 1 Monovalent fragment composed of structural domains; (ii) F(ab') 2 A fragment comprising two Fab fragments connected by a disulfide bridge in the hinge region; (iii) a fragment consisting of V H and CH 1 (iv) an Fd fragment consisting of a single-arm V L and V H (v) dAb fragment (Ward et al., Nature 341:544-546, 1989), which consists of V H domains; and (vi) isolated complementarity determining regions (CDRs). Thus, an "antibody fragment" or "antigen binding fragment" may comprise a portion of a full-length antibody, typically its antigen binding or variable region. Examples of antibody fragments or antigen binding fragments include Fab, Fab', F(ab') 2 and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

[0043] As used herein, "bispecific antibody" or "BsAb" refers to an antibody that can simultaneously bind to two targets with different structures (e.g., two different target antigens, two different epitopes on the same target antigen). A variety of different bispecific antibody structures are known in the art. In some embodiments, each antigen-binding portion in the bispecific antibody includes a V H and / or V L region; in some such embodiments, V H and / or VL The V regions are those found in a particular monoclonal antibody. In some embodiments, a bispecific antibody contains two antigen-binding portions, each of which includes a V region from a different monoclonal antibody. H and / or V L In some embodiments, the bispecific antibody contains two antigen-binding moieties, wherein one of the two antigen-binding moieties comprises a region having a V H and / or V L region of the immunoglobulin molecule, the V H and / or V L The second antigen binding portion comprises a CDR region from the first monoclonal antibody; and the second antigen binding portion comprises a CDR region from the first monoclonal antibody; H and / or V L Antibody fragments (e.g., Fab, F(ab'), F(ab') 2 , Fd, Fv, dAB, scFv, etc.), the V H and / or V L The region contains the CDRs from the second monoclonal antibody.

[0044] As used herein, the term "conjugated" refers to the association of two molecules by any method known to those skilled in the art. Suitable types of association include chemical bonds and physical bonds. Chemical bonds include, for example, covalent bonds and coordination bonds. Physical bonds include, for example, hydrogen bonds, dipole interactions, van der Waals forces, electrostatic interactions, hydrophobic interactions, and aromatic ring stacking.

[0045] As used herein, the term "diabodies" refers to small antibody fragments with two antigen-binding sites contained in the same polypeptide chain in conjunction with a light chain variable domain (V L ) connected to the heavy chain variable domain (V H )(V H V L ). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are more fully described in, for example, EP 404,097; WO 93 / 11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

[0046] As used herein, the term "single-chain antibody" or "single-chain Fv (scFv)" refers to the two domains V and Fv fragments. L and V H Single-chain antibody molecules may include polymers having multiple individual molecules, such as dimers, trimers, or other polymers. vThe two domains of the fragment V L and V H The two proteins are encoded by separate genes, but they can be joined by synthetic linkers using recombinant methods to make them into a single protein chain in which V L and V H The domains are paired to form monovalent molecules called single-chain Fvs (scFvs). Bird et al. (1988) Science 242:423-426 and Huston et al. (1988) Proc. Natl. Acad Sci. USA 85:5879-5883. Such single-chain antibodies can be prepared by recombinant techniques or by enzymatic or chemical cleavage of intact antibodies.

[0047] Fragments of any of the foregoing antibodies are obtained using conventional techniques known to those of skill in the art, and the fragments are screened for binding specificity and neutralization activity in the same manner as are intact antibodies.

[0048] As used herein, "antigen" refers to a molecule to which an antibody (or antigen-binding fragment thereof) can selectively bind. The target antigen can be a protein, carbohydrate, nucleic acid, lipid, hapten, or other naturally occurring or synthetic compound. In some embodiments, the target antigen can be a polypeptide (e.g., a DLL3 polypeptide that includes a DLL3 extracellular domain). Antigens can also be administered to an animal to generate an immune response in the animal.

[0049] The term "antigen-binding fragment" refers to a fragment of an intact immunoglobulin structure having a polypeptide portion responsible for binding to an antigen. Examples of antigen-binding fragments that can be used in the technology of the present invention include scFv, (scFv) 2 , scFv-Fc, Fab, Fab' and F(ab') 2 , but not limited to this.

[0050] "Binding affinity" refers to the strength of the total non-covalent interaction between a single binding site of a molecule (e.g., an antibody) and the molecule's binding partner (e.g., an antigen or antigenic peptide). The affinity of a molecule X for its partner Y can generally be expressed by the dissociation constant (K D ) is represented by. Affinity can be measured by standard methods known in the art (including those described herein). Low affinity complexes contain antibodies that generally tend to dissociate easily from the antigen, while high affinity complexes contain antibodies that generally tend to remain bound to the antigen for a longer period of time.

[0051] As used herein, the term "biological sample" means a sample material derived from living cells. Biological samples can include tissues, cells, proteins or membrane extracts of cells separated from a subject and biological fluids (e.g., ascites or cerebrospinal fluid (CSF)), as well as tissues, cells and fluids present in a subject. The biological samples of the technology of the present invention include but are not limited to samples taken from: breast tissue, kidney tissue, cervix, endometrium, head or neck, gallbladder, parotid tissue, prostate, brain, pituitary gland, kidney tissue, muscle, esophagus, stomach, small intestine, colon, liver, spleen, pancreas, thyroid tissue, heart tissue, lung tissue, bladder, adipose tissue, lymph node tissue, uterus, ovarian tissue, adrenal tissue, testicular tissue, tonsil, thymus, blood, hair, cheek, skin, serum, plasma, CSF, sperm, prostatic fluid, semen, urine, feces, sweat, saliva, sputum, mucus, bone marrow, lymph and tears. Biological samples can also be obtained from a biopsy of an internal organ or from cancer. Biological samples can be obtained from subjects for diagnosis or research; or can be obtained from individuals who have never been ill, as controls or for basic research. Samples can be obtained by standard methods, including, for example, venipuncture and surgical biopsy. In certain embodiments, the biological sample is a sputum sample or a tissue sample obtained by needle biopsy or surgical biopsy.

[0052] As used herein, the term "CDR-grafted antibody" means an antibody in which at least one CDR of a "recipient" antibody is replaced by a CDR "graft" having the desired antigen specificity from a "donor" antibody.

[0053] As used herein, the term "chimeric antibody" refers to an antibody in which the Fc constant region of a monoclonal antibody from one species (e.g., a mouse Fc constant region) is replaced with the Fc constant region of an antibody from another species (e.g., a human Fc constant region) using recombinant DNA technology. See generally, Robinson et al., PCT / US86 / 02269; Akira et al., European Patent Application 184,187; Taniguchi, European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., WO 86 / 01533; Cabilly et al., U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 0125,023; Better et al., Science 240:1041-1043, 1988; Liu et al., Proc. Natl. Acad. Sci. USA 84:3439-3443, 1987; Liu et al., J. Immunol 139:3521-3526, 1987; Sun et al., Proc. Natl. Acad. Sci. USA 84:214-218, 1987; Nishimura et al., Cancer Res 47:999-1005, 1987; Wood et al., Nature 314:446-449, 1885; and Shaw et al., J. Natl. Cancer Inst. 80:1553-1559, 1988.

[0054] As used herein, the term "consensus FR" means the framework (FR) antibody region in the consensus immunoglobulin sequence. The FR region of an antibody does not contact the antigen.

[0055] As used herein, a "control" is an alternative sample used in an experiment for comparison purposes. A control can be "positive" or "negative." For example, where the purpose of an experiment is to determine the relevance of the efficacy of a therapeutic agent for the treatment of a particular type of disease, a positive control (a compound or composition known to exhibit the desired therapeutic effect) and a negative control (a subject or sample that does not receive treatment or receives a placebo) are typically used.

[0056] As used herein, the term "effective amount" refers to an amount sufficient to achieve the desired therapeutic and / or preventive effect, such as an amount that causes the prevention or reduction of a disease or condition described herein or one or more signs or symptoms associated with a disease or condition described herein. In the case of therapeutic or preventive applications, the amount of the composition applied to the subject will vary according to the composition, the extent, type and severity of the disease, and according to individual characteristics (such as general health, age, sex, body weight and drug tolerance). The technician will be able to determine the appropriate dosage based on these and other factors. The composition can also be administered in combination with one or more additional therapeutic compounds. In the methods described herein, the therapeutic composition can be administered to a subject having one or more signs or symptoms of a disease or condition described herein. As used herein, a "therapeutically effective amount" of a composition refers to a composition level in which the physiological effects of a disease or condition are improved or eliminated. The therapeutically effective amount can be administered in one or more administrations.

[0057] An "isolated" or "purified" polypeptide or peptide is substantially free of cellular material or other contaminating polypeptides from the cell or tissue source from which the agent is derived, or substantially free of chemical precursors or other chemicals in the case of chemical synthesis. For example, an isolated anti-DLL3 antibody or antigen-binding fragment of the present technology will be free of substances that would interfere with the diagnostic or therapeutic use of the agent. Such interfering substances may include enzymes, hormones, and other protein and non-protein solutes.

[0058] As used herein, the term "epitope" means a protein determinant capable of specific binding to an antibody. An epitope is generally composed of chemically active surface groups of a molecule (such as amino acids or sugar side chains) and generally has specific three-dimensional structural characteristics, as well as specific charge characteristics. The difference between a conformational epitope and a non-conformational epitope is that in the presence of a denaturing solvent, binding to a conformational epitope rather than a non-conformational epitope is lost. In some embodiments, an "epitope" of a DLL3 protein is a region of the protein to which an anti-DLL3 antibody of the present technology specifically binds. In some embodiments, the epitope is a conformational epitope or a non-conformational epitope. In order to screen for anti-DLL3 antibodies that bind to an epitope, a conventional cross-blocking assay may be performed, such as the assay described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, edited by Harlow and David Lane (1988). This assay can be used to determine whether an anti-DLL3 antibody binds to the same site or epitope as an anti-DLL3 antibody of the present technology. Alternatively or additionally, epitope mapping may be performed by methods known in the art. For example, the antibody sequence can be mutagenized, such as by alanine scanning, to identify contact residues. In a different approach, peptides corresponding to different regions of the DLL3 protein can be used in competition assays with multiple test antibodies, or with a test antibody and an antibody with a characterized or known epitope.

[0059] As used herein, "expression" includes one or more of the following: transcription of a gene into a precursor mRNA; splicing and other processing of the precursor mRNA to produce a mature mRNA; mRNA stability; translation of the mature mRNA into protein (including codon usage and tRNA availability); and glycosylation and / or other modifications of the translation product (if required for proper expression and function).

[0060] As used herein, the term "gene" means a segment of DNA that contains all the information for regulated biosynthesis of an RNA product, including promoters, exons, introns, and other untranslated regions that control expression.

[0061] As used herein, "homology" or "identity" or "similarity" refers to the sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing the positions in each sequence, which can be aligned for comparison purposes. When the position in the compared sequence is occupied by the same base or amino acid, the molecules are homologous at that position. The degree of homology between sequences varies with the number of matching or homologous positions shared by the sequences. A polynucleotide or polynucleotide region (or polypeptide or polypeptide region) has a certain percentage (e.g., at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%) of "sequence identity" with another sequence, which means that, when aligned, the bases (or amino acids) of that percentage are the same in comparing the two sequences. This alignment and homology or sequence identity percentage can be determined using software programs known in the art. In some embodiments, default parameters are used for alignment. One alignment program is BLAST, using default parameters. Specifically, the programs are BLASTN and BLASTP, using the following default parameters: genetic code = standard; filter = none; chain = two; cutoff = 60; expectation = 10; matrix = BLOSUM62; description = 50 sequences; sorting mode = high score (HIGH SCORE); database = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translation + SwissProtein + SPupdate + PIR. Detailed information on these programs can be found at the National Center for Biotechnology Information. Biologically equivalent polynucleotides are those polynucleotides with a specified homology percentage and encoding polypeptides with the same or similar biological activity. If two sequences share less than 40% identity or less than 25% identity with each other, the sequences are considered "unrelated" or "non-homologous".

[0062] As used herein, the "humanized" form of a non-human (e.g., mouse) antibody is a chimeric antibody that contains minimal sequences derived from non-human immunoglobulins. For the most part, a humanized antibody is a human immunoglobulin in which the hypervariable region residues of the receptor are replaced by hypervariable region residues (donor antibody) from a non-human species (e.g., mouse, rat, rabbit, or non-human primate) with the desired specificity, affinity, and ability. In some embodiments, the Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. In addition, a humanized antibody may include residues not found in the receptor antibody or the donor antibody. These modifications are performed to further improve antibody performance such as binding affinity. Typically, a humanized antibody will include at least one, usually two variable domains (e.g., Fab, Fab', F(ab') 2The humanized antibody may be a humanized antibody comprising substantially all of an immunoglobulin (Fv), wherein all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin, and all or substantially all of the FR regions are those of a human immunoglobulin consensus FR sequence, but the FR regions may include one or more amino acid substitutions that improve binding affinity. The number of these amino acid substitutions in the FR is generally no more than 6 in the H chain and no more than 3 in the L chain. The humanized antibody may also optionally include at least a portion of an immunoglobulin constant region (Fc), typically at least a portion of a human immunoglobulin constant region. For further details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). See, e.g., Ahmed and Cheung, FEBS Letters 588(2):288-297 (2014); Saxena and Wu, Frontiers in immunology 7:580 (2016).

[0063] As used herein, the term "hypervariable region" refers to the amino acid residues in an antibody that are responsible for antigen binding. A hypervariable region generally comprises amino acid residues from a "complementarity determining region" or "CDR" (e.g., V L before and after residues 24-34 (L1), 50-56 (L2), and 89-97 (L3), and V H 31-35B (H1), 50-65 (H2), and 95-102 (H3) in the sequence (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and / or those residues from the "hypervariable loops" (e.g., V L Residues 26-32 (L1), 50-52 (L2), and 91-96 (L3) in V H 26-32 (H1), 52A-55 (H2) and 96-101 (H3) (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).

[0064] As used herein, when used in the context of two or more nucleic acids or polypeptide sequences, the term "identical" or "identity" percentage refers to two or more sequences or subsequences that are identical or have a specified percentage of identical amino acid residues or nucleotides (i.e., about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity over a specified region (e.g., a nucleotide sequence encoding an antibody described herein or an amino acid sequence of an antibody described herein) when compared and aligned for maximum correspondence over a comparison window or a specific region), as measured using a BLAST or BLAST 2.0 sequence comparison algorithm using the default parameters described below or by manual alignment and visual inspection (e.g., NCBI website). Such sequences are then referred to as "substantially identical". This term also refers to or can be applied to the complement of a test sequence. The term also includes sequences with deletions and / or additions, as well as those with substitutions. In some embodiments, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or that is 50-100 amino acids or nucleotides in length.

[0065] As used herein, the term "intact antibody" or "intact immunoglobulin" means an antibody having at least two heavy (H) chain polypeptides and two light (L) chain polypeptides interconnected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated herein as HCVR or V H ) and the heavy chain constant region. The heavy chain constant region consists of three domains CH 1 , CH 2 and CH 3 Each light chain is composed of a light chain variable region (abbreviated herein as LCVR or V L ) and the light chain constant region. The light chain constant region consists of a domain C L Composition. H and V L The regions can be further subdivided into regions of high variability, termed complementarity determining regions (CDRs), interspersed with more conserved regions, termed framework regions (FRs). H and V L It consists of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR 1 , CDR 1 , FR 2 , CDR 2 , FR 3 , CDR 3 , FR 4The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant regions of antibodies can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.

[0066] As used herein, the term "individual", "patient" or "subject" can be a single organism, a vertebrate, a mammal or a human. In some embodiments, the individual, patient or subject is a human.

[0067] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, that is, except for a possible naturally occurring mutation that may be present in a small amount, the individual antibodies constituting the population are identical. For example, a monoclonal antibody may be an antibody derived from a single clone (including any eukaryotic, prokaryotic or phage clone) rather than a method for producing it. A monoclonal antibody composition exhibits a single binding specificity and affinity to a specific epitope. Monoclonal antibodies are highly specific for a single antigenic site. In addition, compared to conventional (polyclonal) antibody preparations that typically include different antibodies for different determinants (epitopes), each monoclonal antibody is for a single determinant on an antigen. The modifier "monoclonal" indicates that the antibody is characterized by being obtained from a substantially homogeneous antibody population, and should not be construed as requiring the antibody to be produced by any ad hoc method. Monoclonal antibodies can be prepared using a variety of techniques known in the art, including, for example, but not limited to, hybridoma, recombinant and phage display techniques. For example, the monoclonal antibody to be used according to the method of the invention can be prepared by the hybridoma method originally described by Kohler et al., Nature 256:495 (1975), or can be prepared by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567). For example, "monoclonal antibodies" can also be isolated from phage antibody libraries using the techniques described by Clackson et al., Nature 352:624-628 (1991) and Marks et al., J. Mol. Biol. 222:581-597 (1991).

[0068] As used herein, the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal compounds, isotonic and absorption delaying compounds, etc. that are compatible with pharmaceutical administration. Pharmaceutically acceptable carriers and their formulations are known to those skilled in the art and are described, for example, in Remington's Pharmaceutical Sciences (20th edition, A. Gennaro, 2000, Lippincott ed., Williams & Wilkins, Philadelphia, PA.).

[0069] As used herein, the term "polyclonal antibody" means a preparation of antibodies derived from at least two (2) different antibody-producing cell lines. The use of this term includes preparations of at least two (2) antibodies containing antibodies that specifically bind to different epitopes or regions of an antigen.

[0070] As used herein, the term "polynucleotide" or "nucleic acid" means any RNA or DNA, which can be unmodified or modified RNA or DNA. Polynucleotides include, but are not limited to, single-stranded and double-stranded DNA, DNA as a mixture of single-stranded and double-stranded regions, single-stranded and double-stranded RNA, RNA as a mixture of single-stranded and double-stranded regions, and hybrid molecules comprising DNA and RNA, which can be single-stranded or more generally double-stranded or a mixture of single-stranded and double-stranded regions. In addition, polynucleotides refer to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNA or RNA containing one or more modified bases, and DNA or RNA to which the backbone is modified for stability or other reasons.

[0071] As used herein, the terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer comprising two or more amino acids linked to each other by peptide bonds or modified peptide bonds (i.e., peptide isosteres). Polypeptides refer to both short chains commonly referred to as peptides, glycopeptides or oligomers, and longer chains commonly referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. Polypeptides include amino acid sequences modified by natural processes (such as post-translational processing) or by chemical modification techniques well known in the art.

[0072] As used herein, "prevention" or "preventing" of a disorder or condition refers to a compound that, in a statistical sample, reduces the occurrence of the disorder or condition in treated samples relative to untreated control samples, or delays the onset of or reduces the severity of one or more symptoms of the disorder or condition relative to untreated control samples.

[0073] As used herein, the term "recombinant" when used with respect to, for example, a cell or a nucleic acid, protein or vector, indicates that the cell, nucleic acid, protein or vector has been modified by the introduction of a heterologous nucleic acid or protein or by the alteration of a native nucleic acid or protein, or that the material is derived from a cell so modified. Thus, for example, a recombinant cell expresses genes not found in the native (non-recombinant) form of the cell, or expresses native genes that are otherwise abnormally expressed, under-expressed, or not expressed at all.

[0074] As used herein, the term "separate" therapeutic use refers to the simultaneous or substantially simultaneous administration of at least two active ingredients by different routes.

[0075] As used herein, the term "sequential" therapeutic use refers to the administration of at least two active ingredients at different times, with the same or different routes of administration. More specifically, sequential use refers to the entire administration of one active ingredient before the administration of the other one or more active ingredients begins. Thus, one active ingredient can be administered a few minutes, hours, or days before the administration of the other one or more active ingredients. In this case, there is no simultaneous treatment.

[0076] As used herein, the term "simultaneous" therapeutic use refers to the administration of at least two active ingredients by the same route and at the same time or substantially at the same time.

[0077] As used herein, "specific binding" refers to a molecule (e.g., an antibody or antigen-binding fragment thereof) that recognizes and binds to another molecule (e.g., an antigen) but does not substantially recognize and bind to other molecules. As used herein, the terms "specifically bind," "specifically binds to," or "specific for" a particular molecule (e.g., a polypeptide or an epitope on a polypeptide) can be defined, for example, by a molecule having about 10 -4 M, 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M or 10 -12 M of K D The term "specifically binds" may also refer to binding in which a molecule (e.g., an antibody or antigen-binding fragment thereof) binds to a specific polypeptide (e.g., a DLL3 polypeptide) or an epitope on a specific polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

[0078] As used herein, the term "therapeutic agent" is intended to mean a compound that, when present in an effective amount, produces a desired therapeutic effect on a subject in need thereof.

[0079] As used herein, "treating" or "treatment" encompasses treating a disease or disorder described herein in a subject, such as a human, and includes: (i) inhibiting the disease or disorder, i.e., preventing its development; (ii) alleviating the disease or disorder, i.e., causing regression of the disorder; (iii) slowing the progression of the disorder; and / or (iv) inhibiting, alleviating, or slowing the progression of one or more symptoms of the disease or disorder. In some embodiments, treatment means that symptoms associated with the disease are, for example, alleviated, reduced, cured, or in a state of remission.

[0080] It is also understood that the various treatment modalities for disorders as described herein are intended to mean "substantially," which includes complete treatment but also less than complete treatment, and in which some biologically or medically relevant result is achieved. The treatment can be continuous, extended treatment for chronic diseases, or a single or several administrations for acute condition treatment.

[0081] One or more amino acid sequence modifications of the anti-DLL3 antibodies described herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of the anti-DLL3 antibodies are prepared by introducing appropriate nucleotide changes into the antibody nucleic acid or by peptide synthesis. Such modifications include, for example, deletions and / or insertions and / or substitutions of residues within the antibody amino acid sequence. Any combination of deletions, insertions and substitutions may be made to obtain the desired antibody, as long as the resulting antibody has the desired properties. Modifications also include changes in the glycosylation pattern of the protein. The sites of greatest interest for substitution mutagenesis include the hypervariable regions, but FR changes are also contemplated. "Conservative substitutions" are shown in the table below.

[0082] One type of substitution variant involves replacing one or more hypervariable region residues of a parent antibody. A convenient method for generating such substitution variants involves affinity maturation using phage display. In particular, several hypervariable region sites (e.g., 6-7 sites) are mutated to produce all possible amino acid substitutions at each site. The antibody variants thus produced are displayed as fusions of the gene III product of M13 packaged in each particle in a monovalent manner from filamentous phage particles. The variants displayed by phage display are then screened for their biological activity (e.g., binding affinity), as disclosed herein. In order to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues that contribute significantly to antigen binding. Alternatively or additionally, analyzing the crystal structure of the antigen-antibody complex may be beneficial to identify the contact points between the antibody and the antigen. According to the technology described in detail herein, such contact residues and adjacent residues are candidates for substitution. Once such variants are produced, this group of variants is screened as described herein, and antibodies with similar or better properties in one or more related assays can be selected for further development. Delta-like 3 (DLL3)

[0083] In fruit flies, Notch signaling is primarily mediated by Notch receptors. Delta is one of the fruit fly Notch ligands that can activate signaling in neighboring cells. Humans have four known Notch receptors (NOTCH1 to NOTCH4) and three homologs of Delta, called Delta-like ligands: DLL1, DLL3, and DLL4. Unlike DLL1 and DLL4, DLL3 is reported to inhibit Notch signaling rather than activate it.

[0084] DLL3 (also known as delta-like 3 or SCDO1) is a member of the delta-like family of Notch DSL ligands. Representative DLL3 protein orthologs include, but are not limited to, humans (Accession No. NP_058637 (SEQ ID NO: 50) and NP_982353 (SEQ ID NO: 51)), chimpanzees (Accession No. XP_003316395 (SEQ ID NO: 52)), mice (Accession No. NP_031892 (SEQ ID NO: 53)) and rats (Accession No. NP_446118 (SEQ ID NO: 54)). In humans, the DLL3 gene consists of 8 exons, spanning 9.5 kBp, and is located on chromosome 19q13. Alternative splicing within the last exon produces a 2389 bp transcript (Accession No. NM_016941 (SEQ ID NO: 55)) and a 2052 bp transcript (Accession No. NM_203486 (SEQ ID NO: 56)). The former transcript encodes a protein of 618 amino acids in length (Accession No. NP_058637 (SEQ ID NO: 50)), while the latter encodes a protein of 587 amino acids in length (Accession No. NP_982353 (SEQ ID NO: 51)). Figure 8A-B The two protein isoforms of DLL3 share 100% overall identity between their extracellular and transmembrane domains, differing only in that the longer isoform contains an extended cytoplasmic tail region containing 32 additional residues at the carboxyl terminus of the protein.

[0085] Both isoforms can be detected in tumor cells. Indeed, aberrant DLL3 expression (genotype and / or phenotype) is associated with various tumorigenic cell subpopulations, such as cancer stem cells and tumor-initiating cells. Thus, the present disclosure provides DLL3 antibodies that can be particularly useful for targeting such cells (e.g., cancer stem cells, tumor-initiating cells, and cancers, such as small cell lung cancer, large cell neuroendocrine carcinoma, pulmonary neuroendocrine carcinoma, extrapulmonary neuroendocrine carcinoma, and melanoma), thereby facilitating the treatment, management, or prevention of oncological disorders. Immunoglobulin-related compositions of the present invention

[0086] The present technology describes methods and compositions for producing and using anti-DLL3 immunoglobulin-related compositions (e.g., anti-DLL3 antibodies or antigen-binding fragments thereof). The anti-DLL3 immunoglobulin-related compositions of the present disclosure can be used to diagnose or treat DLL3-related cancers (e.g., small cell lung cancer, large cell neuroendocrine cancer, pulmonary neuroendocrine cancer, extrapulmonary neuroendocrine cancer, and melanoma). Anti-DLL3 immunoglobulin-related compositions within the scope of the present technology include, for example, but not limited to, monoclonal antibodies, chimeric antibodies, humanized antibodies, bispecific antibodies, and diabodies that specifically bind to a target polypeptide, a homolog, derivative, or fragment thereof. The present disclosure also provides an antigen-binding fragment of any anti-DLL3 antibody disclosed herein, wherein the antigen-binding fragment is selected from Fab, F(ab)'2, Fab', scF v and F v .

[0087] The present technology discloses anti-DLL3 antibodies that can promote internalization of DLL3-antibody complexes and thus can be used to deliver toxic payloads to tumor cells.

[0088] Figure 3A-Figure 6B Provided are V H and V L The nucleotide and amino acid sequences and CDR sequences of the antibodies disclosed herein are also provided in the following table: H and V L Amino acid sequence and CDR sequence.

[0089] In one aspect, the present disclosure provides an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain immunoglobulin variable domain (V H ) and light chain immunoglobulin variable domain (V L ), wherein (a) V H Contains V selected from the following H -CDR1 sequence, V H -CDR2 sequence and V H- CDR3 sequences: (i) SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively; (ii) SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15, respectively; (iii) SEQ ID NO: 23, SEQ ID NO: 24 and SEQ ID NO: 25, respectively; and (iv) SEQ ID NO: 33, SEQ ID NO: 34 and SEQ ID NO: 35, respectively; and / or (b) the V L Contains V selected from the following L -CDR1 sequence, V L -CDR2 sequence and V L - CDR3 sequences: (i) SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively; (ii) SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, respectively; (iii) SEQ ID NO: 28, SEQ ID NO: 29 and SEQ ID NO: 30, respectively; and (iv) SEQ ID NO: 38, SEQ ID NO: 39 and SEQ ID NO: 40, respectively. In some embodiments, the antibody further comprises an Fc domain of any isotype, such as but not limited to IgG (including IgG1, IgG2, IgG3 and IgG4), IgA (including IgA1 and IgA2), IgD, IgE or IgM and IgY. Non-limiting examples of constant region sequences include:

[0090] Human IgD constant region, Uniprot: P01880 (SEQ ID NO: 41)

[0091] APTKAPDVFPIISGCRHPKDNSPVVLACLITGYHPTSVTVTWYMGTQSQPQRTFPEIQRRDSYYMTSSQLSTPLQQWRQGEYKCVVQHTASKSKKEIFRWPESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTPECPSHTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLKDAHLTWEVAGKVPTGGVEEGLLERHSNGSQSQHSRLTLPRSLWNAGTSVTCTLNHPSLPPQRLMALREPAAQAPVKLSLNLLASSDPPEAASWLLCEVSGFSPPNILLMWLEDQREVNTSGFAPARPPPQPGSTTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLLNASRSLEVSYVTDHGPMK

[0092] Human IgG1 constant region, Uniprot: P01857 (SEQ ID NO:42)

[0093] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0094] Human IgG2 constant region, Uniprot: P01859 (SEQ ID NO:43)

[0095] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0096] Human IgG3 constant region, Uniprot: P01860 (SEQ ID NO:44)

[0097] ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPGK

[0098] Human IgM constant region, Uniprot: P01871 (SEQ ID NO:45)

[0099] GSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITLSWKYKNNSDISS TRGFPSVLRGGKYAATSQVLLPSKDVMQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVPPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLGQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVAHEALPNRVTERTVDKSTGKPTLYNVSLVMSDTAGTCY

[0100] Human IgG4 constant region, Uniprot: P01861 (SEQ ID NO: 46)

[0101] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0102] Human IgA1 constant region, Uniprot: P01876 (SEQ ID NO: 47)

[0103] ASPTSPKVFPLSLCSTQPDGNVVIACLVQGFFPQEPLSVTWSESGQGVTARNFPPSQDASGDLYTTSSQLTLPATQCLAGKSVTCHVKHYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGVTFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVDGTCY

[0104] Human IgA2 constant region, Uniprot: P01877 (SEQ ID NO:48)

[0105] ASPTSPKVFPLSLDSTPQDGNVVVACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVTCHVKHYTNPSQDVTVPCPVPPPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTANITKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRMAGKPTHVNVSVVMAEVDGTCY

[0106] Human Igκ constant region, Uniprot: P01834 (SEQ ID NO:49)

[0107] TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0108] In some embodiments, the immunoglobulin-related compositions of the present technology comprise a heavy chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or 100% identical to SEQ ID NOs: 41-48. Additionally or alternatively, in some embodiments, the immunoglobulin-related compositions of the present technology comprise a light chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or 100% identical to SEQ ID NO: 49. In some embodiments, the immunoglobulin-related compositions of the present technology bind to the extracellular domain of DLL3. In some embodiments, the epitope is a conformational epitope.

[0109] In another aspect, the present disclosure provides an isolated immunoglobulin-related composition (e.g., an antibody or an antigen-binding fragment thereof) comprising a heavy chain immunoglobulin variable domain (V ) comprising SEQ ID NO: 2, SEQ ID NO: 12, SEQ ID NO: 22, SEQ ID NO: 32, or a variant thereof having one or more conservative amino acid substitutions. H ) amino acid sequence.

[0110] Additionally or alternatively, in some embodiments, the immunoglobulin-related compositions of the present technology comprise a light chain immunoglobulin variable domain (V LLD) comprising SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, or a variant thereof having one or more conservative amino acid substitutions. L ) amino acid sequence.

[0111] In some embodiments, the immunoglobulin-related compositions of the present technology comprise a heavy chain immunoglobulin variable domain (V H ) amino acid sequence and light chain immunoglobulin variable domain (V L ) amino acid sequences: SEQ ID NO: 2 and SEQ ID NO: 7 (7-I1-B); SEQ ID NO: 12 and SEQ ID NO: 17 (2-C8-A); SEQ ID NO: 22 and SEQ ID NO: 27 (10-018-A); and SEQ ID NO: 32 and SEQ ID NO: 37 (6-G23-F).

[0112] In any of the above embodiments of the immunoglobulin-related compositions, the HC and LC immunoglobulin variable domain sequences form an antigen binding site that binds to the extracellular domain of DLL3. In any of the above embodiments of the immunoglobulin-related compositions, the HC and LC immunoglobulin variable domain sequences form an antigen binding site that binds to DLL3 and promotes internalization of the immunoglobulin-related compositions. In some embodiments, the epitope is a conformational epitope.

[0113] In some embodiments, the HC and LC immunoglobulin variable domain sequences are components of the same polypeptide chain. In other embodiments, the HC and LC immunoglobulin variable domain sequences are components of different polypeptide chains. In certain embodiments, the antibody is a full-length antibody.

[0114] In some embodiments, the immunoglobulin-related compositions of the present technology specifically bind to at least one DLL3 polypeptide. In some embodiments, the immunoglobulin-related compositions of the present technology are present in an amount of about 10 -3 M, 10 -4 M, 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M or 10 -12 The dissociation constant (K D ) binds to at least one DLL3 polypeptide. In certain embodiments, the immunoglobulin-related composition is a monoclonal antibody, a chimeric antibody, a humanized antibody, or a bispecific antibody. In some embodiments, the antibody comprises a human antibody framework region.

[0115] In certain embodiments, the immunoglobulin-related compositions include one or more of the following features: (a) a light chain immunoglobulin variable domain sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain immunoglobulin variable domain sequence present in any one of SEQ ID NOs: 7, 17, 27, or 37; and / or (b) a heavy chain immunoglobulin variable domain sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a heavy chain immunoglobulin variable domain sequence present in any one of SEQ ID NOs: 2, 12, 22, or 32. In another aspect, one or more amino acid residues in the immunoglobulin-related compositions provided herein are substituted with another amino acid. The substitution may be a "conservative substitution" as defined herein.

[0116] In certain embodiments, the immunoglobulin-related composition comprises an IgG1 constant region comprising one or more amino acid substitutions selected from N297A and K322A. Additionally or alternatively, in some embodiments, the immunoglobulin-related composition comprises an IgG4 constant region comprising an S228P mutation.

[0117] In some aspects, the anti-DLL3 immunoglobulin-related compositions described herein contain structural modifications to promote rapid binding and cellular uptake and / or slow release. In some aspects, the anti-DLL3 immunoglobulin-related compositions (e.g., antibodies) of the present technology may contain deletions in the CH2 constant heavy chain region to promote rapid binding and cellular uptake and / or slow release. In some aspects, Fab fragments are used to promote rapid binding and cellular uptake and / or slow release. In some aspects, F(ab)' 2 Fragments are used to promote rapid binding and cellular uptake and / or slow release.

[0118] In one aspect, the present invention provides a nucleic acid sequence encoding any of the immunoglobulin-related compositions described herein. Also disclosed herein is a recombinant nucleic acid sequence encoding any of the antibodies described herein. In some embodiments, the nucleic acid sequence is selected from SEQ ID NO: 1, 6, 11, 16, 21, 26, 31 and 36.

[0119] In another aspect, the present technology provides a host cell or expression vector that expresses any nucleic acid sequence encoding any of the immunoglobulin-related compositions described herein.

[0120] The immunoglobulin-related compositions (e.g., anti-DLL3 antibodies) of the present technology can be monospecific, bispecific, trispecific, or have greater multispecificity. Multispecific antibodies can be specific for different epitopes of one or more DLL3 polypeptides, or can be specific for both one or more DLL3 polypeptides and a heterologous composition (e.g., a heterologous polypeptide or a solid support material). See, e.g., WO 93 / 17715; WO 92 / 08802; WO 91 / 00360; WO 92 / 05793; Tutt et al., J. Immunol. 147: 60-69 (1991); U.S. Pat. Nos. 5,573,920; 4,474,893; 5,601,819; 4,714,681; 4,925,648; 6,106,835; Kostelny et al., J. Immunol. 148: 1547-1553 (1992). In some embodiments, the immunoglobulin-related composition is chimeric. In certain embodiments, the immunoglobulin-related composition is humanized.

[0121] The immunoglobulin-related compositions of the present technology can be further recombinantly fused to a heterologous polypeptide at the N-terminus or C-terminus, or chemically conjugated (including covalent and non-covalent conjugation) to a polypeptide or other composition. For example, the immunoglobulin-related compositions of the present technology can be recombinantly fused or conjugated to molecules and effector molecules (such as heterologous polypeptides, drugs or toxins) that can be used as markers in detection assays. See, for example, WO 92 / 08495; WO 91 / 14438; WO 89 / 12624; U.S. Pat. No. 5,314,995; and EP 0 396 387.

[0122] In any of the above-mentioned embodiments of the immunoglobulin-related compositions of the present technology, the antibody or antigen binding fragment can be optionally conjugated with an agent selected from the following: isotopes, dyes, chromogens, contrast agents, drugs, toxins, cytokines, enzymes, enzyme inhibitors, hormones, hormone antagonists, growth factors, radionuclides, metals, liposomes, nanoparticles, RNA, DNA or any combination thereof. In some embodiments, the antibody or antigen binding fragment of the present technology can be combined with a pharmaceutically acceptable carrier. For chemical bonds or physical binding, the functional groups on the immunoglobulin-related compositions are usually associated with the functional groups on the medicament. Alternatively, the functional groups on the medicament are associated with the functional groups on the immunoglobulin-related compositions.

[0123] Functional groups on the medicament and functional groups on the immunoglobulin-related composition can be directly associated. For example, functional groups (e.g., sulfhydryl groups) on the medicament can be associated with functional groups (e.g., sulfhydryl groups) on the immunoglobulin-related composition to form disulfide bonds. Alternatively, the functional groups can be associated through a cross-linking agent (i.e., a linker). Some examples of cross-linking agents are described below. The cross-linking agent can be attached to the medicament or the immunoglobulin-related composition. The number of medicaments or immunoglobulin-related compositions in the conjugate is also limited by the number of functional groups present on the other party. For example, the maximum number of medicaments associated with the conjugate depends on the number of functional groups present on the immunoglobulin-related composition. Alternatively, the maximum number of immunoglobulin-related compositions associated with the medicament depends on the number of functional groups present on the medicament.

[0124] In another embodiment, the conjugate comprises an immunoglobulin-related composition associated with an agent. In one embodiment, the conjugate comprises at least one agent chemically bonded (e.g., conjugated) to at least one immunoglobulin-related composition. The agent can be chemically bonded to the immunoglobulin-related composition by any method known to those skilled in the art. For example, the functional group on the agent can be directly attached to the functional group on the immunoglobulin-related composition. Some examples of suitable functional groups include, for example, amino, carboxyl, sulfhydryl, maleimide, isocyanate, isothiocyanate, and hydroxyl.

[0125] The agent may also be chemically bonded to the immunoglobulin-related composition by a cross-linking agent such as a dialdehyde, carbodiimide, dimaleimide, etc. Cross-linking agents may be obtained, for example, from Pierce Biotechnology, Inc. of Rockford, IL. The Pierce Biotechnology, Inc. website may provide assistance. Additional cross-linking agents include platinum cross-linking agents described in the following documents: U.S. Pat. Nos. 5,580,990; 5,985,566; and 6,133,038 to Kreatech Biotechnology, BV, Amsterdam, The Netherlands.

[0126] Alternatively, the functional groups on the agent and the immunoglobulin-related composition can be the same. Homobifunctional crosslinkers are generally used to crosslink the same functional groups. Examples of homobifunctional crosslinkers include EGS (i.e., ethylene glycol bis[succinimidyl succinate]), DSS (i.e., disuccinimidyl suberate), DMA (i.e., dimethyl adipimidate.2HCl), DTSSP (i.e., 3,3'-dithiobis[sulfosuccinimidyl propionate]), DPDPB (i.e., 1,4-bis-[3'-(2'-pyridyldithio)-propionamido] butane) and BMH (i.e., bismaleimidohexane). Such homobifunctional crosslinkers can also be obtained from Pierce Biotechnology, Inc.

[0127] In other cases, it may be beneficial to cleave the agent from the immunoglobulin-related composition. The website of Pierce Biotechnology, Inc. can also provide assistance to those skilled in the art in selecting a suitable cross-linking agent, which can be cleaved by, for example, an enzyme in the cell. Thus, the agent can be separated from the immunoglobulin-related composition. Examples of cleavable linkers include SMPT (i.e., 4-succinimidyloxycarbonyl-methyl-a-[2-pyridyldithio]toluene), sulfo-LC-SPDP (i.e., sulfosuccinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate), LC-SPDP (i.e., succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate), sulfo-LC-SPDP (e.g., sulfosuccinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate), SPDP (i.e., N-succinimidyl 3-[2-pyridyldithio]-propionamidohexanoate), and AEDP (i.e., 3-[(2-aminoethyl)dithio]propionic acid HCl).

[0128] In another embodiment, the conjugate comprises at least one agent physically bound to at least one immunoglobulin-related composition. The agent can be physically bound to the immunoglobulin-related composition by any method known to those skilled in the art. For example, the immunoglobulin-related composition and the agent can be mixed by any method known to those skilled in the art. The order of mixing is not important. For example, the agent can be physically mixed with the immunoglobulin-related composition by any method known to those skilled in the art. For example, the immunoglobulin-related composition and the agent can be placed in a container and stirred by, for example, shaking the container to mix the immunoglobulin-related composition and the agent.

[0129] The immunoglobulin-related compositions can be modified by any method known to those skilled in the art. For example, as described above, the immunoglobulin-related compositions can be modified by cross-linking agents or functional groups. A. Methods for preparing anti-DLL3 antibodies of the present invention

[0130] Overview. First, a target polypeptide is selected against which antibodies of the present technology can be generated. For example, antibodies can be generated against a full-length DLL3 protein or a portion of the extracellular domain of a DLL3 protein. Techniques for generating antibodies against such target polypeptides are well known to those skilled in the art. Examples of such techniques include, but are not limited to, techniques involving display libraries, xenogeneic or human mice, hybridomas, and the like. Target polypeptides within the scope of the present technology include any polypeptide derived from a DLL3 protein containing an extracellular domain that is capable of eliciting an immune response.

[0131] It will be appreciated that recombinantly engineered antibodies and antibody fragments (eg, antibody-related polypeptides) directed against DLL3 proteins and fragments thereof are suitable for use in accordance with the present disclosure.

[0132] Anti-DLL3 antibodies that can be subjected to the techniques described herein include monoclonal antibodies and polyclonal antibodies, as well as antibody fragments, such as Fab, Fab', F(ab') 2 , Fd, scFv, diabodies, antibody light chains, antibody heavy chains and / or antibody fragments. Methods for producing high yields of antibody Fv-containing polypeptides (e.g., Fab′ and F(ab′) 2 See U.S. Pat. No. 5,648,237.

[0133] Typically, antibodies are obtained from a species of origin. More specifically, nucleic acid or amino acid sequences of the light chain, heavy chain, or variable portions of both of an antibody of the species of origin that is specific for a target polypeptide antigen are obtained. The species of origin is any species that can be used to generate antibodies or antibody libraries of the technology of the present invention, such as rats, mice, rabbits, chickens, monkeys, humans, etc.

[0134] Phage or phagemid display technology is a technology that can be used to derive antibodies of the present invention. The technology used to produce and clone monoclonal antibodies is well known to those skilled in the art. The expression of sequences encoding antibodies of the present invention can be carried out in Escherichia coli.

[0135] Due to the degeneracy of nucleic acid coding sequences, other sequences encoding amino acid sequences that are substantially identical to those of naturally occurring proteins can be used in the practice of the present technology. These sequences include, but are not limited to, nucleic acid sequences including all or part of the nucleic acid sequences encoding the above-mentioned polypeptides, which are altered by substitution of different codons for functionally equivalent amino acid residues within the coding sequence, thereby producing silent changes. It should be understood that the nucleotide sequences of immunoglobulins according to the present technology tolerate up to 25% sequence homology variation as calculated by standard methods ("Current Methods in Sequence Comparison and Analysis," Macromolecule Sequencing and Synthesis, Selected Methods and Applications, pages 127-149, 1998, Alan R. Liss, Inc.), as long as such variants form effective antibodies that recognize DLL3 proteins. For example, one or more amino acid residues within a polypeptide sequence can be substituted by another amino acid of similar polarity, which acts as a functional equivalent, thereby resulting in silent changes. Substitutes for amino acids within the sequence can be selected from other members of the class to which the amino acid belongs. For example, non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. Positively charged (basic) amino acids include arginine, lysine and histidine. Negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Also included within the technical scope of the present invention are proteins or fragments or derivatives thereof, which are differentially modified during or after translation, such as by glycosylation, proteolytic cleavage, connection to antibody molecules or other cellular ligands, etc. In addition, the nucleic acid sequence encoding the immunoglobulin can be mutated in vitro or in vivo to generate and / or destroy the translation, initiation and / or termination of the sequence, or to produce variations in the coding region and / or form new restriction endonuclease sites or destroy the previously existing sites to facilitate further in vitro modification. Any mutagenesis technique known in the art may be used, including but not limited to in vitro site-directed mutagenesis (J. Biol. Chem. 253:6551, use of Tab linkers (Pharmacia)), etc.

[0136] Preparation of polyclonal antisera and immunogens. Methods for producing antibodies or antibody fragments of the present technology generally include immunizing a subject (usually a non-human subject, such as a mouse or rabbit) with a purified DLL3 protein or a fragment thereof or with a cell expressing a DLL3 protein or a fragment thereof. A suitable immunogenic preparation may contain, for example, a recombinantly expressed DLL3 protein or a chemically synthesized DLL3 peptide. Using standard techniques for polyclonal and monoclonal antibody preparation, the extracellular domain of a DLL3 protein, or a portion or fragment thereof, may be used as an immunogen to produce anti-DLL3 antibodies that bind to a DLL3 protein, or a portion or fragment thereof.

[0137] The full-length DLL3 protein or a fragment thereof can be used as an immunogen as a fragment. In some embodiments, the DLL3 fragment comprises the extracellular domain of DLL3, so that antibodies raised against the peptide form specific immune complexes with the DLL3 protein.

[0138] The extracellular domain of DLL3 is 466 amino acids in length, spanning amino acids 27-492 of the full-length DLL3 protein. In some embodiments, the antigenic DLL3 peptide comprises at least 5, 8, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, or 450 amino acid residues. Longer antigenic peptides are sometimes desirable rather than shorter antigenic peptides, depending on the application and according to methods well known to those skilled in the art. Multimers of a given epitope are sometimes more effective than monomers.

[0139] If desired, the immunogenicity of the DLL3 protein (or fragment thereof) can be increased by fusion or conjugation with a carrier protein, such as keyhole limpet hemocyanin (KLH) or ovalbumin (OVA). Many such carrier proteins are known in the art. The DLL3 protein can also be combined with a conventional adjuvant, such as Freund's complete or incomplete adjuvant, to enhance the subject's immune response to the polypeptide. Various adjuvants used to enhance the immune response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surfactants (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), human adjuvants (e.g., Bacille Calmette-Guerin and Corynebacterium parvum), or similar immunostimulatory compounds. These techniques are standard in the art.

[0140] In describing the present technology, immune responses may be described as "primary" or "secondary" immune responses. A primary immune response, also referred to as a "protective" immune response, refers to an immune response generated in an individual as a result of initial exposure (e.g., initial "immunization") to a particular antigen (e.g., a DLL3 protein). In some embodiments, immunization may be performed by vaccinating an individual with a vaccine containing the antigen. For example, the vaccine may be a DLL3 vaccine comprising one or more DLL3 protein-derived antigens. Over time, the primary immune response may weaken or diminish, and may even disappear or at least become so diminished that it is undetectable. Therefore, the present technology also relates to a "secondary" immune response, also referred to herein as a "memory immune response." The term secondary immune response refers to an immune response elicited in an individual after a primary immune response has been generated.

[0141] Thus, a secondary immune response may be elicited, for example, to enhance an existing immune response that has been weakened or attenuated, or to regenerate a previous immune response that has disappeared or can no longer be detected. A secondary or memory immune response may be a humoral (antibody) response or a cellular response. A secondary or memory humoral response occurs following stimulation of memory B cells generated upon initial presentation of an antigen. A delayed type hypersensitivity (DTH) reaction is a CD4 + A type of cellular secondary or memory immune response mediated by T cells. The first exposure to an antigen primes the immune system, and one or more additional exposures result in DTH.

[0142] After appropriate immunization, anti-DLL3 antibodies can be prepared from the subject's serum. If desired, antibody molecules directed against DLL3 protein can be isolated from a mammal (eg, from blood) and further purified by well-known techniques such as polypeptide A chromatography to obtain an IgG fraction.

[0143] Monoclonal antibodies. In one embodiment of the present technology, the antibody is an anti-DLL3 monoclonal antibody. For example, in some embodiments, the anti-DLL3 monoclonal antibody can be a human or mouse anti-DLL3 monoclonal antibody. To prepare monoclonal antibodies against DLL3 protein or derivatives, fragments, analogs or homologs thereof, any technique that produces antibody molecules by continuous cell line culture can be used. Such techniques include, but are not limited to, hybridoma technology (see, e.g., Kohler and Milstein, 1975. Nature 256: 495-497); trioma technology; human B cell hybridoma technology (see, e.g., Kozbor et al., 1983. Immunol. Today 4: 72) and EBV hybridoma technology to produce human monoclonal antibodies (see, e.g., Cole et al., 1985. In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies can be used in the practice of the present invention technology, and can be obtained by using human hybridomas (see, for example, Cote et al., 1983. Proc. Natl. Acad. Sci. USA 80: 2026-2030) or by transforming human B cells with Epstein Barr virus in vitro (see, for example, Cole et al., 1985. In: MONOCLONALANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). For example, a nucleic acid group encoding an antibody region can be isolated. PCR using primers derived from sequences encoding antibody conserved regions is used to amplify sequences encoding antibody portions from the population, and then DNA encoding antibodies or fragments thereof (such as variable domains) is reconstructed from the amplified sequences. Such amplified sequences can also be fused to DNA encoding other proteins, such as phage coats or bacterial cell surface proteins, to express and display fusion polypeptides on phages or bacteria. The amplified sequences can then be expressed and further selected or isolated based on, for example, the affinity of the expressed antibody or fragment thereof for an antigen or epitope present on the DLL3 protein. Alternatively, hybridomas expressing anti-DLL3 monoclonal antibodies can be prepared by immunizing a subject and then isolating the hybridomas from the spleen of the subject using conventional methods. See, for example, Milstein et al. (Galfre and Milstein, Methods Enzymol (1981) 73:3-46). Screening of hybridomas using standard methods will produce monoclonal antibodies with different specificities (i.e., to different epitopes) and affinities.Selected monoclonal antibodies with desired properties (e.g., DLL3 binding) can be used as expressed by hybridomas, can be conjugated to molecules such as polyethylene glycol (PEG) to alter their properties, or the cDNA encoding the monoclonal antibody can be isolated, sequenced, and manipulated in various ways. Synthetic dendromeric trees can be added to reactive amino acid side chains such as lysine to enhance the immunogenic properties of the DLL3 protein. Additionally, CPG-dinucleotide technology can be used to enhance the immunogenic properties of the DLL3 protein. Other manipulations include substitution or deletion of specific aminoacyl residues that promote antibody instability during storage or after administration to a subject, and affinity maturation techniques to improve the affinity of antibodies for the DLL3 protein.

[0144] Hybridoma technology. In some embodiments, the antibodies of the present technology are anti-DLL3 monoclonal antibodies produced by hybridomas, the hybridomas comprising B cells obtained from transgenic non-human animals (e.g., transgenic mice) having a genome comprising a human heavy chain transgene and a light chain transgene fused to immortalized cells. Hybridoma technology includes those known in the art and taught in the following literature: Harlow et al., Antibodies: A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 349 (1988); Hammerling et al., Monoclonal Antibodies And T-Cell Hybridomas, 563-681 (1981). Other methods for producing hybridomas and monoclonal antibodies are well known to those skilled in the art.

[0145] Phage display technology. As noted above, antibodies of the present technology can be produced by applying recombinant DNA technology and phage display technology. For example, anti-DLL3 antibodies can be prepared using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles that carry polynucleotide sequences encoding the functional antibody domains. Phages with desired binding properties are selected from a library or combinatorial antibody library (e.g., human or mouse) by direct selection with antigen (usually an antigen bound or captured to a solid surface or bead). The phage used in these methods are typically filamentous phage, including fd and M13 with Fab, Fv, or disulfide-stabilized Fv antibody domains recombinantly fused to phage gene III or gene VIII proteins. Furthermore, the methods are suitable for the construction of Fab expression libraries (see, eg, Huse et al., Science 246: 1275-1281, 1989) to rapidly and efficiently identify monoclonal Fab fragments having the desired specificity for a DLL3 polypeptide, eg, a polypeptide or a derivative, fragment, analog or homolog thereof.Other examples of phage display methods that can be used to make antibodies of the present technology include those disclosed in the following references: Huston et al., Proc. Natl. Acad. Sci USA, 85:5879-5883, 1988; Chaudhary et al., Proc. Natl. Acad. Sci USA, 87:1066-1070, 1990; Brinkman et al., J. Immunol. Methods 182:41-50, 1995; Ames et al., J. Immunol. Methods 184:177-186, 1995; Kettleborough et al., Eur. J. Immunol. 24:952-958, 1994; Persic et al., Gene 187:9-18, 1997; Burton et al., Advances in Immunology 57:191-280,1994; PCT / GB91 / 01134; WO 90 / 02809; WO 91 / 10737; WO 92 / 01047; WO 92 / 18619; WO 93 / 11236; WO 95 / 15982; WO 95 / 20401; WO 96 / 06213; WO 92 / 01047 (Medical Research Council et al); WO 97 / 08320 (Morphosys); WO92 / 01047 (CAT / MRC); WO 91 / 17271 (Affymax) and U.S. Patent Nos. 5,698,426, 5,223,409, 5,403,484, 5,580,717, 5,427,908, 5,750,753, 5,821,047, 5,571,698, 5,427,908, 5,516,637, 5,780,225, 5,658,727 and 5,733,743. U.S. Patent No. 6,753,136 to Lohning has described a method for displaying polypeptides on the surface of phage particles by attaching the polypeptides via disulfide bonds. As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to produce complete antibodies (including human antibodies) or any other desired antigen binding fragments and expressed in any desired host (including mammalian cells, insect cells, plant cells, yeast and bacteria). For example, Fab, Fab' and F(ab') are recombinantly produced. 2Fragment technology can also be utilized using methods known in the art, such as those disclosed in WO 92 / 22324; Mullinax et al., BioTechniques 12:864-869, 1992; and Sawai et al., AJRI 34:26-34, 1995; and Better et al., Science 240:1041-1043, 1988.

[0146] Typically, hybrid antibodies or hybrid antibody fragments cloned into display vectors can be selected for appropriate antigens to identify variants that retain good binding activity because the antibodies or antibody fragments will be present on the surface of phage or phagemid particles. See, e.g., Barbas III et al., Phage Display, A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001). However, other vector formats can be used for this process, such as cloning antibody fragment libraries into lytic phage vectors (modified T7 or Lambda Zap systems) for selection and / or screening.

[0147] Expression of Recombinant Anti-DLL3 Antibodies. As described above, antibodies of the present technology can be produced by applying recombinant DNA techniques. Recombinant polynucleotide constructs encoding anti-DLL3 antibodies of the present technology generally include expression control sequences operably linked to the coding sequence of the anti-DLL3 antibody chain, including naturally associated or heterologous promoter regions. Therefore, another aspect of the present technology includes vectors containing one or more nucleic acid sequences encoding the anti-DLL3 antibodies of the present technology. For recombinant expression of one or more polypeptides of the present technology, nucleic acids containing all or a portion of the nucleotide sequence encoding the anti-DLL3 antibody are inserted into a suitable cloning vector or expression vector (i.e., a vector containing the necessary elements for transcription and translation of the inserted polypeptide coding sequence) by recombinant DNA techniques well known in the art and described in detail below. Methods for generating a variety of vector populations have been described in U.S. Patent Nos. 6,291,160 and 6,680,192 to Lerner et al.

[0148] In general, expression vectors useful in recombinant DNA techniques are usually in the form of plasmids. In this disclosure, "plasmid" and "vector" are used interchangeably because plasmids are the most commonly used form of vectors. However, the present technology is intended to include such other forms of expression vectors that are not technically plasmids and perform equivalent functions, such as viral vectors (e.g., replication-defective retroviruses, adenoviruses, and adeno-associated viruses). Such viral vectors allow infection of a subject and expression of the construct in the subject. In some embodiments, the expression control sequence is a eukaryotic promoter system in a vector capable of transforming or transfecting a eukaryotic host cell. Once the vector is incorporated into a suitable host, the host is maintained under conditions suitable for high-level expression of the nucleotide sequence encoding the anti-DLL3 antibody and for collecting and purifying the anti-DLL3 antibody (e.g., cross-reactive anti-DLL3 antibody). See US2002 / 0199213 in general. These expression vectors are typically replicable in the host organism as an episome or as an integral part of the host chromosomal DNA. Typically, the expression vector contains a selection marker, such as ampicillin resistance or hygromycin resistance, to allow detection of cells transformed with the desired DNA sequence. The vector may also encode a signal peptide that can be used to direct secretion of the extracellular antibody fragment, such as pectin lyase. See U.S. Pat. No. 5,576,195.

[0149] The recombinant expression vector of the present technology comprises a nucleic acid encoding a protein having DLL3 binding properties, and the recombinant expression vector is in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vector includes one or more regulatory sequences selected according to the host cell for expression, and the one or more regulatory sequences are operably linked to the nucleic acid sequence to be expressed. In the recombinant expression vector, "operably linked" is intended to mean that the target nucleotide sequence is linked to one or more regulatory sequences in a manner that allows the nucleotide sequence to be expressed (e.g., in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in the following literature: Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, California (1990). Regulatory sequences include those that direct constitutive expression of nucleotide sequences in many types of host cells and those that direct expression of nucleotide sequences only in certain host cells (e.g., tissue-specific regulatory sequences). Those skilled in the art will appreciate that the design of the expression vector may depend on factors such as the choice of the host cell to be transformed, the expression level of the desired polypeptide, etc. Typical regulatory sequences that can be used as promoters for expression of recombinant polypeptides (e.g., anti-DLL3 antibodies) include, for example, but not limited to, promoters of 3-phosphoglycerate kinase and other glycolytic enzymes. Inducible yeast promoters include, among others, promoters from alcohol dehydrogenase, isocytochrome C, and enzymes responsible for maltose and galactose utilization. In one embodiment, the polynucleotide encoding the anti-DLL3 antibody of the present technology is operably linked to the ara B promoter and is expressible in the host cell. See U.S. Pat. No. 5,028,530. The expression vector of the present technology can be introduced into a host cell to produce a polypeptide or peptide encoded by the nucleic acid described herein, including a fusion polypeptide (e.g., anti-DLL3 antibody, etc.).

[0150] Another aspect of the present technology relates to host cells expressing anti-DLL3 antibodies, which contain nucleic acids encoding one or more anti-DLL3 antibodies. The recombinant expression vectors of the present technology can be designed to express anti-DLL3 antibodies in prokaryotic or eukaryotic cells. For example, anti-DLL3 antibodies can be expressed in bacterial cells (such as E. coli), insect cells (using baculovirus expression vectors), fungal cells (such as yeast, yeast cells), or mammalian cells. Suitable host cells are further discussed in the following literature: Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, California (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example, using T7 promoter regulatory sequences and T7 polymerase. Methods that can be used to prepare and screen for polypeptides (such as anti-DLL3 antibodies) having predetermined properties via expression of randomly generated polynucleotide sequences have been previously described. See U.S. Patent Nos. 5,763,192; 5,723,323; 5,814,476; 5,817,483; 5,824,514; 5,976,862; 6,492,107; 6,569,641.

[0151] The expression of polypeptides in prokaryotes is most often carried out in Escherichia coli using vectors containing constitutive or inducible promoters that direct the expression of fusion or non-fusion polypeptides. Fusion vectors add many amino acids to the polypeptide encoded therein, usually to the amino terminus of the recombinant polypeptide. Such fusion vectors usually have three purposes: (i) increase the expression of the recombinant polypeptide; (ii) increase the solubility of the recombinant polypeptide; and (iii) assist in the purification of the recombinant polypeptide by acting as a ligand in affinity purification. Typically, in a fusion expression vector, a proteolytic cleavage site is introduced at the junction of the fusion part and the recombinant polypeptide so that the recombinant polypeptide can be separated from the fusion part after the fusion polypeptide is purified. Such enzymes and their homologous recognition sequences include factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67:31-40), pMAL (New England Biolabs, Beverly, Massachusetts) and pRIT5 (Pharmacia, Piscataway, New Jersey), which fuse glutathione S-transferase (GST), maltose E binding polypeptide or polypeptide A to the target recombinant polypeptide, respectively.

[0152] Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, CA (1990) 60-89). Pack et al., U.S. Pat. Nos. 6,294,353; 6,692,935, have described methods for targeted assembly of different active peptides or protein domains via polypeptide fusion to produce multifunctional polypeptides. One strategy to maximize expression of recombinant polypeptides (e.g., anti-DLL3 antibodies) in E. coli is to express the polypeptide in a host bacterium that is impaired in its ability to proteolytically cleave the recombinant polypeptide. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, CA (1990) 119-128. Another strategy is to change the nucleic acid sequence of the nucleic acid to be inserted into the expression vector so that the individual codons for each amino acid are codons preferentially used in the expression host (e.g., E. coli) (see, e.g., Wada et al., 1992. Nucl. Acids Res. 20: 2111-2118). Such changes in the nucleic acid sequence of the present invention can be performed by standard DNA synthesis techniques.

[0153] In another embodiment, the anti-DLL3 antibody expression vector is a yeast expression vector. Examples of vectors for expression in Saccharomyces cerevisiae include pYepSec1 (Baldari et al., 1987. EMBO J. 6: 229-234), pMFa (Kurjan and Herskowitz, Cell 30: 933-943, 1982), pJRY88 (Schultz et al., Gene 54: 113-123, 1987), pYES2 (Invitrogen Corporation, San Diego, California) and picZ (Invitrogen Corp, San Diego, California). Alternatively, baculovirus expression vectors can be used to express anti-DLL3 antibodies in insect cells. Baculovirus vectors that can be used to express polypeptides (eg, anti-DLL3 antibodies) in cultured insect cells (eg, SF9 cells) include the pAc series (Smith et al., Mol. Cell. Biol. 3:2156-2165, 1983) and the pVL series (Lucklow and Summers, 1989. Virology 170:31-39).

[0154] In yet another embodiment, a nucleic acid encoding an anti-DLL3 antibody of the present technology is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include, for example, but are not limited to, pCDM8 (Seed, Nature 329:840, 1987) and pMT2PC (Kaufman et al., EMBO J. 6:187-195, 1987). When used in mammalian cells, the control functions of the expression vector are typically provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma virus, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells that can be used to express the anti-DLL3 antibodies of the present technology, see, for example, Sambrook et al., MOLECULAR CLONING: ALABORATORY MANUAL. 2nd Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, Chapters 16 and 17.

[0155] In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid in a specific cell type (e.g., tissue-specific regulatory elements). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al., Genes Dev. 1: 268-277, 1987), lymphoid-specific promoters (Calame and Eaton, Adv. Immunol. 43: 235-275, 1988), promoters of T cell receptors (Winoto and Baltimore, EMBO J. 8: 729-733, 1989) and immunoglobulins (Banerji et al., 1983. Cell 33: 729-740; Queen and Baltimore, Cell 33: 741-748, 1983.), neuron-specific promoters (e.g., neurofilament promoters; Byrne and Ruddle, Proc. Natl. Acad. Sci. USA 86:5473-5477, 1989), pancreas-specific promoters (Edlund et al., 1985. Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally regulated promoters are also contemplated, such as the mouse hox promoter (Kessel and Gruss, Science 249:374-379, 1990) and the alpha-fetoprotein promoter (Campes and Tilghman, Genes Dev. 3:537-546, 1989).

[0156] Another aspect of the inventive method relates to a host cell into which a recombinant expression vector of the inventive technology has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It should be understood that such terms refer not only to specific subject cells, but also to the progeny or potential progeny of such cells. Because certain modifications may occur in the offspring due to mutations or environmental influences, such progeny may in fact be different from the parental cell, but are still included in the scope of the term as used herein.

[0157] The host cell can be any prokaryotic or eukaryotic cell. For example, anti-DLL3 antibodies can be expressed in bacterial cells (such as E. coli), insect cells, yeast or mammalian cells. Mammalian cells are suitable hosts for expressing nucleotide segments encoding immunoglobulins or fragments thereof. See Winnacker, From Genes To Clones, (VCH Publishers, NY, 1987). Many suitable host cell lines capable of secreting complete heterologous proteins have been developed in the art, and the suitable host cell lines include Chinese hamster ovary (CHO) cell lines, various COS cell lines, HeLa cells, L cells and myeloma cell lines. In some embodiments, the cells are non-human. The expression vectors of these cells can include expression control sequences, such as replication origins, promoters, enhancers, and necessary processing information sites, such as ribosome binding sites, RNA splicing sites, polyadenylation sites and transcription terminator sequences. Queen et al., Immunol. Rev. 89: 49, 1986. Illustrative expression control sequences are promoters derived from endogenous genes, cytomegalovirus, SV40, adenovirus, bovine papilloma virus, etc. Co et al., J Immunol. 148: 1149, 1992. Other suitable host cells are known to those skilled in the art.

[0158] Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional conversion or transfection techniques. As used herein, the terms "conversion" and "transfection" are intended to refer to various art-recognized techniques for introducing exogenous nucleic acid (e.g., DNA) into host cells, including calcium phosphate or calcium chloride coprecipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, gene guns, or transfection based on viruses. Other methods for transforming mammalian cells include using polybrene, protoplast fusion, liposomes, electroporation, and microinjection (generally referring to Sambrook et al., Molecular Cloning). Suitable methods for transforming or transfecting host cells can be found in the following documents: Sambrook et al. (MOLECULAR CLONING: ALABORATORY MANUAL. 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) and other laboratory manuals. Depending on the type of cell host, the vector containing the target DNA segment can be transferred to the host cell by a well-known method.

[0159] For stable transfection of mammalian cells, it is known that only a small fraction of cells may integrate the foreign DNA into their genome, depending on the expression vector and transfection technique used. In order to identify and select these integrants, a gene encoding a selectable marker (e.g., resistance to antibiotics) is typically introduced into the host cell along with the gene of interest. Various selectable markers include those that confer resistance to drugs such as G418, hygromycin, and methotrexate. Nucleic acid encoding the selectable marker may be introduced into the host cell on the same vector as the vector encoding the anti-DLL3 antibody, or may be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid may be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

[0160] Host cells (e.g., prokaryotic or eukaryotic host cells in culture) comprising an anti-DLL3 antibody of the present technology can be used to produce (i.e., express) a recombinant anti-DLL3 antibody. In one embodiment, the method comprises culturing a host cell (into which a recombinant expression vector encoding an anti-DLL3 antibody has been introduced) in a suitable culture medium, thereby producing the anti-DLL3 antibody. In another embodiment, the method further comprises the step of isolating the anti-DLL3 antibody from the culture medium or the host cell. Once expressed, the anti-DLL3 antibody, e.g., a collection of anti-DLL3 antibodies or anti-DLL3 antibody-related polypeptides, is purified from the culture medium and host cells. The anti-DLL3 antibody can be purified according to standard procedures in the art (including HPLC purification, column chromatography, gel electrophoresis, etc.). In one embodiment, the anti-DLL3 antibody is produced in a host organism by the method of U.S. Pat. No. 4,816,397 to Boss et al. Typically, the anti-DLL3 antibody chain is expressed along with a signal sequence and is thereby released into the culture medium. However, if the anti-DLL3 antibody chain is not naturally secreted by the host cell, the anti-DLL3 antibody chain can be released by treatment with a mild detergent. Purification of recombinant polypeptides is well known in the art and includes ammonium sulfate precipitation, affinity chromatography purification techniques, column chromatography, ion exchange purification techniques, gel electrophoresis, and the like (see generally Scopes, Protein Purification (Springer-Verlag, New York, 1982)).

[0161] Polynucleotides encoding anti-DLL3 antibodies, such as the coding sequence of an anti-DLL3 antibody, can be incorporated into a transgene for introduction into the genome of a transgenic animal and subsequent expression in the milk of the transgenic animal. See, e.g., U.S. Patent Nos. 5,741,957; 5,304,489 and 5,849,992. Suitable transgenes include coding sequences for light and / or heavy chains operably linked to promoters and enhancers from mammary gland-specific genes, such as casein or beta-lactoglobulin. For the generation of transgenic animals, the transgene can be microinjected into a fertilized oocyte, or the transgene can be incorporated into the genome of an embryonic stem cell and the nucleus of such a cell transferred into an enucleated oocyte.

[0162] Single-chain antibodies. In one embodiment, the anti-DLL3 antibodies of the present technology are single-chain anti-DLL3 antibodies. According to the present technology, the technology can be applied to produce single-chain antibodies specific for DLL3 protein (see, e.g., U.S. Patent No. 4,946,778). Examples of technologies that can be used to produce single-chain Fvs and antibodies of the present technology include those described in the following documents: U.S. Patent Nos. 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology, 203:46-88, 1991; Shu, L. et al., Proc. Natl. Acad. Sci. USA, 90:7995-7999, 1993; and Skerra et al., Science 240:1038-1040, 1988.

[0163] Chimeric and humanized antibodies. In one embodiment, the anti-DLL3 antibodies of the present technology are chimeric anti-DLL3 antibodies. In one embodiment, the anti-DLL3 antibodies of the present technology are humanized anti-DLL3 antibodies. In one embodiment of the present technology, the donor antibody and the recipient antibody are monoclonal antibodies from different species. For example, the recipient antibody is a human antibody (to minimize its antigenicity in humans), in which case the resulting CDR-grafted antibody is referred to as a "humanized" antibody.

[0164] Recombinant anti-DLL3 antibodies comprising human and non-human portions (such as chimeric monoclonal antibodies and humanized monoclonal antibodies) can be prepared using standard recombinant DNA techniques and are within the scope of the present technology. For certain uses, including in vivo uses of the anti-DLL3 antibodies of the present technology and uses of these agents in in vitro detection assays, chimeric or humanized anti-DLL3 antibodies can be used. Such chimeric monoclonal antibodies and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art. Such useful methods include, for example, but are not limited to, those described in International Application No. PCT / US86 / 02269; U.S. Pat. No. 5,225,539; European Patent No. 184187; European Patent No. 171496; European Patent No. 173494; PCT International Publication No. WO 86 / 01533; U.S. Pat. Nos. 4,816,567; 5,225,539; European Patent No. 125023; Better et al., 1988. Science 240:1041-1043; Liu et al., 1987. Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al., 1987. J. Immunol. 139:3521-3526; Sun et al., 1987. Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al., 1987. Cancer Res. 47:999-1005; Wood et al., 1985. Nature 314:446-449; Shaw et al., 1988. J. Natl. Cancer Inst. 80:1553-1559; Morrison (1985) Science 229:1202-1207; Oi et al. (1986) BioTechniques 4:214; Jones et al., 1986. Nature 321:552-525; Verhoeyan et al., 1988. Science 239:1534; Morrison, Science 229:1202, 1985; Oi et al., BioTechniques 4:214, 1986; Gillies et al., J. Immunol. Methods, 125:191-202, 1989; U.S. Patent No. 5,807,715; and Beidler et al., 1988. J. Immunol. 141:4053-4060.For example, antibodies can be humanized using a variety of techniques including CDR grafting (EP 0 239 400; WO 91 / 09967; U.S. Pat. Nos. 5,530,101; 5,585,089; 5,859,205; 6,248,516; EP 460 167), veneering or resurfacing (EP 0 592 106; EP 0 519 596; Padlan E.A., Molecular Immunology, 28:489-498, 1991; Studnicka et al., Protein Engineering 7:805-814, 1994; Roguska et al., PNAS 91:969-973, 1994), and chain shuffling (U.S. Pat. No. 5,565,332). In one embodiment, the cDNA encoding the murine anti-DLL3 monoclonal antibody is digested with a specifically selected restriction endonuclease to remove the sequence encoding the Fc constant region and replace it with the equivalent portion of the cDNA encoding the human Fc constant region (see Robinson et al., PCT / US86 / 02269; Akira et al., European Patent Application 184,187; Taniguchi, European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., WO 86 / 01533; Cabilly et al., U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988) Science 240:1041-1043; Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al. (1987) J Immunol 139:3521-3526; Sun et al. (1987) Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al. (1987) Cancer Res 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al. (1988) J. Natl. Cancer Inst. 80:1553-1559; U.S. Pat. No. 6,180,370; U.S. Pat. Nos. 6,300,064; 6,696,248; 6,706,484; 6,828,422.

[0165] In one embodiment, the present technology provides the construction of humanized anti-DLL3 antibodies that are less likely to induce a human anti-mouse antibody (hereinafter "HAMA") response while still having effective antibody effector function. As used herein, the terms "human" and "humanized" with respect to antibodies refer to any antibody that is expected to elicit a weak immunogenic response in a human subject that is therapeutically tolerable. In one embodiment, the present technology provides humanized anti-DLL3 antibodies, heavy chain and light chain immunoglobulins.

[0166] CDR antibodies. In some embodiments, the anti-DLL3 antibodies of the present technology are anti-DLL3 CDR antibodies. Typically, the donor and recipient antibodies used to generate anti-DLL3 CDR antibodies are monoclonal antibodies from different species; typically, the recipient antibody is a human antibody (to minimize its antigenicity in humans), in which case the resulting CDR-grafted antibody is called a "humanized" antibody. The graft may have a single V of the recipient antibody. H or V L A single CDR (or even a portion of a single CDR) within a H and V L In general, all three CDRs in all variable domains of the recipient antibody will be replaced by the corresponding donor CDRs, but only as many replacements are required so that the resulting CDR-grafted antibody fully binds to the DLL3 protein. Methods for producing CDR-grafted and humanized antibodies are taught in the following literature: U.S. Pat. No. 5,585,089 to Queen et al.; U.S. Pat. No. 5,693,761; U.S. Pat. No. 5,693,762; and U.S. Pat. No. 5,225,539 to Winter; and EP 0682040. It can be used to prepare V H and V L Polypeptide methods are taught in Winter et al., US Patent Nos. 4,816,397; 6,291,158; 6,291,159; 6,291,161; 6,545,142; EP0368684; EP0451216; and EP0120694.

[0167] After selecting suitable framework region candidates from the same family and / or same family member, one or both of the heavy chain and light chain variable regions are produced by transplanting the CDR from the species of origin into the hybrid framework region. Conventional methods known to those skilled in the art can be used to complete the assembly of hybrid antibodies or hybrid antibody fragments with hybrid variable chain regions in any of the above aspects. For example, DNA sequences encoding hybrid variable domains as described herein (i.e., frameworks based on target species and CDRs from species of origin) can be produced by oligonucleotide synthesis and / or PCR. Suitable restriction enzymes can also be used to separate the nucleic acids encoding CDR regions from species of origin antibodies, and connected to the target species framework by connecting with suitable ligases. Alternatively, the framework regions of the variable chains of species of origin antibodies can be changed by site-directed mutagenesis.

[0168] Since hybrids are constructed from selections between multiple candidates corresponding to each framework region, there are many sequence combinations suitable for construction according to the principles described herein. Thus, libraries of hybrids can be assembled whose members have different combinations of individual framework regions. Such libraries can be electronic database collections of sequences or physical collections of hybrids.

[0169] This process does not usually change the FRs of the recipient antibody flanking the grafted CDRs. However, one skilled in the art can sometimes improve the antigen binding affinity of the resulting anti-DLL3 CDR-grafted antibody by replacing certain residues of a given FR to make the FR more similar to the corresponding FR of the donor antibody. Suitable substitution positions include amino acid residues adjacent to the CDR, or amino acid residues that can interact with the CDR (see, e.g., US 5,585,089, especially columns 12-16). Alternatively, one skilled in the art can start with the donor FR and modify it to make it more similar to the recipient FR or human consensus FR. Techniques for making these modifications are known in the art. In particular, if the resulting FR conforms to the human consensus FR at that position or is at least 90% or more identical to such a consensus FR, doing so may not significantly increase the antigenicity of the resulting modified anti-DLL3 CDR-grafted antibody compared to the same antibody with fully human FRs.

[0170] Bispecific antibodies (BsAb). Bispecific antibodies are antibodies that can simultaneously bind to two targets with different structures (e.g., two different target antigens, two different epitopes on the same target antigen). BsAb can be prepared, for example, by combining heavy chains and / or light chains that recognize different epitopes of the same or different antigens. In some embodiments, through molecular function, a bispecific binder binds to one antigen (or epitope) on one of its two binding arms (a VH / VL pair) and binds to a different antigen (or epitope) on its second arm (a different VH / VL pair). According to this definition, a bispecific binder has two different antigen binding arms (both specificity and CDR sequences are different) and is monovalent for each antigen it binds.

[0171] The bispecific antibodies (BsAb) and bispecific antibody fragments (BsFab) of the present technology have at least one arm that specifically binds to, for example, DLL3 and at least one other arm that specifically binds to a second target antigen. In certain embodiments, the BsAb is capable of binding to tumor cells that express the DLL3 antigen on the cell surface.

[0172] A variety of bispecific fusion proteins can be produced using molecular engineering. For example, BsAbs utilizing complete immunoglobulin frameworks (e.g., IgG), single-chain variable fragments (scFv), or combinations thereof have been constructed. In some embodiments, the bispecific fusion protein is bivalent, comprising, for example, a scFv with a single binding site for an antigen and a Fab fragment with a single binding site for a second antigen. In some embodiments, the bispecific fusion protein is bivalent, comprising, for example, a scFv with a single binding site for an antigen and another scFv fragment with a single binding site for a second antigen. In other embodiments, the bispecific fusion protein is tetravalent, comprising, for example, an immunoglobulin (e.g., IgG) with two binding sites for an antigen and two identical scFvs for a second antigen. It has been shown that the BsAb consisting of two scFv units in series is a clinically successful bispecific antibody format. In some embodiments, the BsAb comprises two single-chain variable fragments (scFv) in series, which are designed to connect the scFvs that bind tumor antigens (e.g., DLL3) to the scFvs that bind different target antigens.

[0173] The latest methods for producing BsAbs include engineered recombinant monoclonal antibodies with additional cysteine ​​residues that make them more firmly cross-linked than more common immunoglobulin isotypes. See, for example, FitzGerald et al., Protein Eng. 10 (10): 1221-1225 (1997). Another method is an engineered recombinant fusion protein that connects two or more different single-chain antibodies or antibody fragment segments with the desired dual specificity. See, for example, Coloma et al., Nature Biotech. 15: 159-163 (1997). A variety of bispecific fusion proteins can be produced using molecular engineering.

[0174] Bispecific fusion proteins linking two or more different single-chain antibodies or antibody fragments are produced in a similar manner. Recombinant methods can be used to produce a variety of fusion proteins. In some specific embodiments, the BsAb according to the present technology comprises an immunoglobulin containing a heavy chain and a light chain and an scFv. In some specific embodiments, the scFv is linked to the C-terminus of the heavy chain of any DLL3 immunoglobulin disclosed herein. In some specific embodiments, the scFv is linked to the C-terminus of the light chain of any DLL3 immunoglobulin disclosed herein. In various embodiments, the scFv is linked to the heavy chain or light chain via a linker sequence. The appropriate linker sequence necessary for in-frame linking of the heavy chain Fd to the scFv is introduced into the V L and V κ The DNA fragment encoding the scFv was then ligated into a staging vector containing a DNA sequence encoding the CH1 domain. The resulting scFv-CH1 construct was excised and ligated to a V vector containing a DNA sequence encoding the DLL3 antibody. H The obtained vector can be used to transfect appropriate host cells, such as mammalian cells, to express the bispecific fusion protein.

[0175] In some embodiments, the length of the linker is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acids. In some embodiments, the linker is characterized in that it tends not to adopt a rigid three-dimensional structure, but to provide flexibility (e.g., a first and / or second antigen binding site) for the polypeptide. In some embodiments, based on the specific characteristics of the BsAb, such as increased stability, a linker is used in the BsAb described herein. In some embodiments, the BsAb of the present invention technology comprises G4 In some specific embodiments, the BsAb of the present invention comprises (G 4 S) n A linker wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more.

[0176] Fc modifications. In some embodiments, an anti-DLL3 antibody of the present technology comprises a variant Fc region, wherein the variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region (or a parent Fc region) such that the affinity of the molecule for an Fc receptor (e.g., an FcγR) is altered, provided that the variant Fc region has no substitutions at positions that directly contact an Fc receptor based on crystallographic and structural analyses of Fc-Fc receptor interactions (e.g., those disclosed by Sondermann et al., Nature, 406:267-273 (2000)). Examples of positions within the Fc region that directly contact an Fc receptor (e.g., an FcγR) include amino acids 234-239 (hinge region), amino acids 265-269 (B / C loop), amino acids 297-299 (C7E loop), and amino acids 327-332 (F / G) loop.

[0177] In some embodiments, the anti-DLL3 antibodies of the present technology have altered affinity for activating and / or inhibitory receptors, wherein the variant Fc region has one or more amino acid modifications, wherein the one or more amino acid modifications are N297 to alanine or K322 to alanine.

[0178] Glycosylation modifications. In some embodiments, the anti-DLL3 antibodies of the present technology have an Fc region that contains variant glycosylation compared to a parent Fc region. In some embodiments, the variant glycosylation includes the absence of fucose; in some embodiments, the variant glycosylation is due to expression in GnT1-deficient CHO cells.

[0179] In some embodiments, the antibodies of the present technology may have modified glycosylation sites relative to an appropriate reference antibody that binds to an antigen of interest (e.g., DLL3) without altering the functionality of the antibody, such as binding activity to the antigen. As used herein, "glycosylation site" includes any specific amino acid sequence in an antibody to which an oligosaccharide (i.e., a carbohydrate containing two or more monosaccharides linked together) will be specifically and covalently attached.

[0180] Oligosaccharide side chains are usually connected to the backbone of the antibody via N-linked or O-linked. N-linked glycosylation refers to the attachment of the oligosaccharide moiety to the side chain of an asparagine residue. O-linked glycosylation refers to the attachment of the oligosaccharide moiety to a hydroxyamino acid, such as serine, threonine. For example, an Fc-glycoform (hDLL3-IgGln) lacking certain oligosaccharides (including fucose) and terminal N-acetylglucosamine can be produced in special CHO cells and exhibits enhanced ADCC effector function.

[0181] In some embodiments, the carbohydrate content of the immunoglobulin-related compositions disclosed herein is modified by adding or deleting glycosylation sites. Methods for modifying the carbohydrate content of antibodies are well known in the art and are included in the present technology, see, for example, U.S. Patent No. 6,218,149; EP 0359096B1; U.S. Patent Publication No. US2002 / 0028486; International Patent Application Publication WO 03 / 035835; U.S. Patent Publication No. 2003 / 0115614; U.S. Patent No. 6,218,149; U.S. Patent No. 6,472,511; The above patents are all incorporated herein by reference in their entirety. In some embodiments, the carbohydrate content of an antibody (or its related part or component) is modified by deleting one or more endogenous carbohydrate parts of the antibody. In some specific embodiments, the present technology includes deleting the glycosylation site of the Fc region of the antibody by modifying the asparagine at position 297 to alanine.

[0182] Engineered glycoforms can be used for a variety of purposes, including but not limited to enhancing or reducing effector function. Engineered glycoforms can be produced by any method known to those skilled in the art, such as by using engineered or variant expression strains, by co-expression with one or more enzymes (e.g., N-acetylglucosamine transferase III (GnTIII)), by expressing molecules comprising Fc regions in various organisms or cell lines from various organisms, or by modifying one or more carbohydrates after molecules comprising Fc regions have been expressed. Methods for generating engineered glycoforms are known in the art and include, but are not limited to, those described in Umana et al., 1999, Nat. Biotechnol. 17:176-180; Davies et al., 2001, Biotechnol. Bioeng. 74:288-294; Shields et al., 2002, J. Biol. Chem. 277:26733-26740; Shinkawa et al., 2003, J. Biol. Chem. 278:3466-3473; U.S. Patent No. 6,602,684; U.S. Patent Application Serial No. 10 / 277,370; U.S. Patent Application Serial No. 10 / 113,929; International Patent Application Publication Nos. WO 00 / 61739A1; WO 01 / 292246A1; WO 02 / 311140A1; WO 02 / 30954A1; POTILLEGENT TM Technology (Biowa, Inc., Princeton, NJ); GLYCOMAB TM Glycosylation engineering technology (GLYCART biotechnology AG, Zurich, Switzerland); each of these documents is incorporated herein by reference in its entirety. See, for example, International Patent Application Publication No. WO 00 / 061739; U.S. Patent Application Publication No. 2003 / 0115614; Okazaki et al., 2004, JMB, 336: 1239-49.

[0183] Fusion protein. In one embodiment, the anti-DLL3 antibody of the present technology is a fusion protein. When fused to a second protein, the anti-DLL3 antibody of the present technology can be used as an antigen tag. Examples of domains that can be fused to a polypeptide include not only heterologous signal sequences, but also other heterologous functional regions. The fusion is not necessarily direct, but can be performed through a linker sequence. Moreover, the fusion protein of the present technology can also be engineered to improve the characteristics of the anti-DLL3 antibody. For example, a region of additional amino acids (particularly charged amino acids) can be added to the N-terminus of the anti-DLL3 antibody to improve stability and durability during purification from a host cell or subsequent processing and storage. In addition, a peptide portion can be added to the anti-DLL3 antibody to facilitate purification. Such regions can be removed before the final preparation of the anti-DLL3 antibody. Adding a peptide portion to facilitate the handling of a polypeptide is a conventional technique well known in the art. The anti-DLL3 antibody of the present technology can be fused to a marker sequence (such as a peptide that facilitates the purification of the fusion polypeptide). In selected embodiments, the marker amino acid sequence is a hexa-histidine peptide, particularly as provided in the pQE vector (QIAGEN, Inc., Chatsworth, CA), many of which are commercially available. As described in Gentz ​​et al., Proc. Natl. Acad. Sci. USA 86:821-824, 1989, for example, hexa-histidine allows for convenient purification of the fusion protein. Another peptide tag that can be used for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. Wilson et al., Cell 37:767, 1984.

[0184] Thus, any of these above-described fusion proteins can be engineered using the polynucleotides or polypeptides of the present technology.Additionally, in some embodiments, the fusion proteins described herein exhibit increased in vivo half-life.

[0185] Fusion proteins with a disulfide-linked dimeric structure (due to IgG) can bind and neutralize other molecules more efficiently than individual monomeric secreted proteins or protein fragments. Fountoulakis et al., J. Biochem. 270:3958-3964, 1995.

[0186] Similarly, EP-AO 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various parts of the constant region of an immunoglobulin molecule and another human protein or a fragment thereof. In many cases, the Fc portion in the fusion protein is beneficial in therapy and diagnosis, and can therefore lead to, for example, improved pharmacokinetic properties. See EP-A 0232262. Alternatively, it may be necessary to delete or modify the Fc portion after expression, detection and purification of the fusion protein. For example, if the fusion protein is used as an antigen for immunization, the Fc portion may hinder therapy and diagnosis. In drug discovery, for example, human proteins (such as hIL-5) have been fused to the Fc portion for the purpose of high-throughput screening assays to identify antagonists of hIL-5. Bennett et al., J.Molecular Recognition 8:52-58, 1995; Johanson et al., J.Biol.Chem., 270:9459-9471, 1995.

[0187] Labeled anti-DLL3 antibodies. In one embodiment, the anti-DLL3 antibodies of the present technology are coupled to a labeling moiety (i.e., a detectable group). The specific label or detectable group conjugated to the anti-DLL3 antibody is not a critical aspect of the present technology, as long as it does not significantly interfere with the specific binding of the anti-DLL3 antibody of the present technology to the DLL3 protein. The detectable group can be any material with detectable physical or chemical properties. Such detectable labels have been well developed in the fields of immunoassays and imaging. In general, almost any label that can be used in such methods can be applied to the present technology. Therefore, a label is any composition that can be detected by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Labels useful in the practice of the present technology include magnetic beads (e.g., Dynabeads TM ), fluorescent dyes (e.g., fluorescein isothiocyanate, Texas Red, rhodamine, etc.), radioactive labels (e.g., 3 H. 14 C. 35 S. 125 I. 121 I. 131 I. 112 In, 99m Tc), other imaging agents such as microbubbles (for ultrasound imaging), 18 F. 11 C. 15 O. 89 Zr (for positron emission tomography), 99m Tc, 111In (for single photon emission tomography), enzymes (e.g., horseradish peroxidase, alkaline phosphatase, and other enzymes commonly used in ELISA), and calorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads. Patents describing the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241, each of which is incorporated herein by reference in its entirety and for all purposes. See also Handbook of Fluorescent Probes and Research Chemicals (6th Edition, Molecular Probes, Inc., Eugene OR.).

[0188] The label can be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. As described above, a variety of labels can be used, the choice of label depending on factors such as the sensitivity required, ease of conjugation to the compound, stability requirements, available instrumentation, and disposal regulations.

[0189] Non-radioactive labels are usually attached by indirect means. Typically, a ligand molecule (e.g., biotin) is covalently bound to the molecule. The ligand is then bound to an anti-ligand (e.g., streptavidin) molecule that is either inherently detectable or covalently bound to a signaling system such as a detectable enzyme, fluorescent compound, or chemiluminescent compound. Many ligands and anti-ligands can be used. In the case of ligands (e.g., biotin, thyroxine, and cortisol) that have natural anti-ligands, the ligand can be used in combination with a labeled naturally occurring anti-ligand. Alternatively, any hapten or antigenic compound can be used in combination with an antibody such as an anti-DLL3 antibody.

[0190] The molecule can also be directly conjugated to the compound that produces the signal, for example, by conjugating with an enzyme or a fluorophore. The target enzyme as a label will mainly be a hydrolase, particularly a phosphatase, an esterase and a glycosidase, or an oxidoreductase, particularly a peroxidase. Fluorescent compounds that can be used as labeling parts include, but are not limited to, for example, fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescent compounds that can be used as labeling parts include, but are not limited to, for example, fluorescein and 2,3-dihydrophthalazinediones, such as luminol. For a review of various labels or signal generating systems that can be used, see U.S. Patent No. 4,391,904.

[0191] The means of detecting the label is well known to those skilled in the art. Therefore, for example, when the label is a radioactive label, the detection means includes a scintillation counter or film, such as in autoradiography. When the label is a fluorescent label, it can be detected by exciting the fluorescent dye with the light of the appropriate wavelength and detecting the fluorescence produced. Fluorescence can be detected in a visual form, by film, by using an electronic detector such as a charge coupled device (CCD) or a photomultiplier tube, etc. Similarly, enzyme labels can be detected by providing a suitable substrate for the enzyme and detecting the resulting reaction product. Finally, simple colorimetric labels can be detected simply by observing the color associated with the label. Therefore, in various dip-dye rod assays, the conjugated gold is often pink, and the various conjugated beads present the color of beads.

[0192] Some assay formats do not require the use of labeled components. For example, an agglutination assay can be used to detect the presence of a target antibody, such as an anti-DLL3 antibody. In this case, antigen-coated particles are agglutinated by a sample containing the target antibody. In this format, no components need to be labeled, and the presence of the target antibody is detected by simple visual inspection. B. Identify and express Anti-DLL3 antibodies of the present invention

[0193] Methods for identifying and / or screening anti-DLL3 antibodies of the present technology. Methods for identifying and screening antibodies against DLL3 polypeptides for antibodies with desired specificity for DLL3 protein (e.g., those that bind to the extracellular domain of DLL3) include any immune-mediated techniques known in the art. Components of the immune response can be detected in vitro by various methods well known to those of ordinary skill in the art. For example, (1) cytotoxic T lymphocytes can be incubated with radiolabeled target cells and the lysis of these target cells detected by the release of radioactivity; (2) helper T lymphocytes can be incubated with antigen and antigen-presenting cells, and cytokine synthesis and secretion measured by standard methods (Windhagen A et al., Immunity, 2:373-80, 1995); (3) antigen-presenting cells can be incubated with whole protein antigen and the presentation of the antigen on MHC detected by T lymphocyte activation assay or biophysical methods (Harding et al., Proc. Natl. Acad. Sci., 86:4230-4, 1989); (4) mast cells can be incubated with agents (cross-linking their Fc-ε receptors) and histamine release measured by enzyme immunoassay (Siraganian et al., TIPS, 4:432-437, 1983); (5) enzyme-linked immunosorbent assay (ELISA).

[0194] Similarly, the products of immune responses in model organisms (e.g., mice) or human subjects can also be detected by various methods well known to those of ordinary skill in the art. For example, (1) the production of antibodies in response to vaccination can be easily detected by standard methods currently used in clinical laboratories, such as ELISA; (2) the migration of immune cells to the site of inflammation can be detected by scratching the skin surface and placing a sterile container to capture the migrating cells at the scratch site (Peters et al., Blood, 72:1310-5, 1988); (3) the use of 3 H-thymidine measures the proliferation of peripheral blood mononuclear cells (PBMCs) in response to mitogens or mixed lymphocyte reactions; (4) the phagocytic capacity of granulocytes, macrophages, and other phagocytes in PBMCs can be measured by placing PBMCs in wells with labeled particles (Peters et al., Blood, 72:1310-5, 1988); and (5) the differentiation of immune system cells can be measured by labeling PBMCs with antibodies to CD molecules (such as CD4 and CD8) and measuring the fraction of PBMCs expressing these markers.

[0195] In one embodiment, the display of DLL3 peptides on the surface of a replicable genetic package is used to select for anti-DLL3 antibodies of the present technology. See, e.g., U.S. Patent Nos. 5,514,548; 5,837,500; 5,871,907; 5,885,793; 5,969,108; 6,225,447; 6,291,650; 6,492,160; EP 585 287; EP 605522; EP 616640; EP1024191; EP 589 877; EP 774 511; EP 844 306. Methods useful for producing / selecting filamentous phage particles containing a phagemid genome encoding a binding molecule with a desired specificity have been described. See, for example, EP 774 511; US ​​5871907; US 5969108; US 6225447; US 6291650; US 6492160.

[0196] In some embodiments, display of DLL3 peptides on the surface of yeast host cells is used to select anti-DLL3 antibodies of the present technology. Methods that can be used to isolate scFv polypeptides by display on the surface of yeast have been described by Kieke et al., Protein Eng. 1997 Nov; 10(11): 1303-10.

[0197] In some embodiments, anti-DLL3 antibodies of the present technology are selected using ribosome display. Methods that can be used to identify ligands in peptide libraries using ribosome display have been described by Mattheakis et al., Proc. Natl. Acad. Sci. USA 91:9022-26, 1994; and Hanes et al., Proc. Natl. Acad. Sci. USA 94:4937-42, 1997.

[0198] In certain embodiments, tRNA display of DLL3 peptides is used to select anti-DLL3 antibodies of the present technology. Methods useful for in vitro selection of ligands using tRNA display have been described by Merryman et al., Chem. Biol., 9:741-46, 2002.

[0199] In one embodiment, RNA display is used to select anti-DLL3 antibodies of the present technology. Methods that can be used to select peptides and proteins using RNA display libraries have been described by Roberts et al., Proc. Natl. Acad. Sci. USA, 94: 12297-302, 1997; and Nemoto et al., FEBS Lett., 414: 405-8, 1997. Methods that can be used to select peptides and proteins using non-natural RNA display libraries have been described by Frankel et al., Curr. Opin. Struct. Biol., 13: 506-12, 2003.

[0200] In some embodiments, an anti-DLL3 antibody of the present technology is expressed in the periplasm of a Gram-negative bacterium and mixed with a labeled DLL3 protein. See WO 02 / 34886. In clones expressing a recombinant polypeptide with affinity for the DLL3 protein, the concentration of the labeled DLL3 protein that binds to the anti-DLL3 antibody is increased, and the cells are allowed to separate from the rest of the library, as described in Harvey et al., Proc. Natl. Acad. Sci. 22:9193-98 2004 and U.S. Patent Publication No. 2004 / 0058403.

[0201] After the desired anti-DLL3 antibody is selected, it is expected that the antibody can be produced in large quantities by any technique known to those skilled in the art, such as prokaryotic or eukaryotic cell expression, etc. Anti-DLL3 antibodies (which are, for example, but not limited to, anti-DLL3 hybrid antibodies or fragments) can be produced by constructing an expression vector encoding an antibody heavy chain using conventional techniques, in which the CDRs and (if necessary) the minimum portion of the variable region framework required to retain the binding specificity of the origin species antibody (engineered according to the techniques described herein) are derived from the origin species antibody, and the remainder of the antibody is derived from a target species immunoglobulin that can be manipulated as described herein, thereby generating a vector for expressing the hybrid antibody heavy chain.

[0202] Measurement of DLL3 Binding. In some embodiments, a DLL3 binding assay refers to an assay format in which a DLL3 protein and an anti-DLL3 antibody are mixed under conditions suitable for binding between the DLL3 protein and the anti-DLL3 antibody and assessing the amount of binding between the DLL3 protein and the anti-DLL3 antibody. The amount of binding is compared to an appropriate control, which can be the amount of binding in the absence of the DLL3 protein, the amount of binding in the presence of a non-specific immunoglobulin composition, or both. The amount of binding can be assessed by any suitable method. Binding assays include, for example, ELISA, radioimmunoassays, scintillation proximity assays, fluorescence energy transfer assays, liquid chromatography, membrane filtration assays, and the like. Biophysical assays for directly measuring DLL3 protein binding to an anti-DLL3 antibody are, for example, nuclear magnetic resonance, fluorescence, fluorescence polarization, surface plasmon resonance (BIACORE chip), bio-layer interferometry, and the like. Specific binding is determined by standard assays known in the art, such as radioligand binding assays, ELISA, FRET, immunoprecipitation, SPR, NMR (2D-NMR), mass spectrometry, and the like. If the specific binding of a candidate anti-DLL3 antibody is at least 1% greater than the binding observed in the absence of the candidate anti-DLL3 antibody, then the candidate anti-DLL3 antibody is useful as an anti-DLL3 antibody of the present technology. Use of anti-DLL3 antibodies of the present invention

[0203] Overview. The antibodies of the present technology can be used in methods known in the art related to the localization and / or quantification of DLL3 polypeptides (e.g., for measuring the level of DLL3 protein in an appropriate physiological sample, for diagnostic methods, for polypeptide imaging, etc.). The anti-DLL3 antibodies of the present technology can be used to isolate DLL3 polypeptides by standard techniques (such as affinity chromatography or immunoprecipitation). The anti-DLL3 antibodies of the present technology can facilitate the purification of natural immunoreactive DLL3 proteins from biological samples such as mammalian serum or cells, as well as the purification of recombinantly produced immunoreactive DLL3 proteins expressed in a host system. In addition, the anti-DLL3 antibodies of the present technology can be used to detect immunoreactive DLL3 proteins (e.g., in plasma, cell lysates, or cell supernatants) to evaluate the abundance and pattern of expression of immunoreactive polypeptides. The anti-DLL3 antibodies of the present technology can be used diagnostically to monitor the level of immunoreactive DLL3 proteins in tissues as part of a clinical testing procedure, for example to determine the efficacy of a given treatment regimen. As described above, detection can be facilitated by coupling (i.e., physically linking) the anti-DLL3 antibodies of the present technology to a detectable substance.

[0204] Detection of DLL3 protein. An exemplary method for detecting the presence of an immunoreactive DLL3 protein in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with an anti-DLL3 antibody of the present technology that is capable of detecting an immunoreactive DLL3 protein, thereby detecting the presence of the immunoreactive DLL3 protein in the biological sample. Detection can be accomplished by a detectable label attached to the antibody.

[0205] The term "labeled" with respect to an anti-DLL3 antibody is intended to encompass direct labeling of the antibody by coupling (i.e., physically linking) a detectable substance to the antibody, as well as indirect labeling of the antibody by reactivity with another compound (e.g., a secondary antibody) that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin so that it can be detected with fluorescently labeled streptavidin.

[0206] In some embodiments, an anti-DLL3 antibody disclosed herein is conjugated to one or more detectable labels. For such uses, the anti-DLL3 antibody can be detectably labeled by covalent or non-covalent attachment of a chromogenic agent, an enzymatic agent, a radioisotopic agent, an isotopic agent, a fluorescent agent, a toxic agent, a chemiluminescent agent, a nuclear magnetic resonance contrast agent, or other label.

[0207] Examples of suitable chromogenic labels include diaminobenzidine and 4-hydroxyazo-benzene-2-carboxylic acid. Examples of suitable enzyme labels include malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triosephosphate isomerase, peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase.

[0208] Examples of suitable radioisotope labels include 3 H. 111 In, 125 I. 131 I. 32 P. 35 S. 14 C. 51 Cr, 57 To, 58 Co. 59 Fe, 75 Se, 152 Eu, 90 Y. 67 Cu, 217 Ci, 211 At 212 Pb, 47 Sc, 109 Pd etc. 111 In is an exemplary isotope when using in vivo imaging because it avoids 125 I or 131 I-labeled DLL3 binding antibodies are dehalogenated by the liver. In addition, this isotope has a gamma emission energy that is more favorable for imaging (Perkins et al., Eur. J. Nucl. Med. 70:296-301 (1985); Carasquillo et al., J. Nucl. Med. 25:281-287 (1987)). For example, a monoclonal antibody conjugated with 1-(p-isothiocyanatobenzyl)-DPTA is 111 In exhibits little uptake in non-tumor tissues (particularly the liver) and enhances the specificity of tumor localization (Esteban et al., J. Nucl. Med. 28:861-870 (1987)). Examples of suitable non-radioactive isotope labels include 157 Gd, 55 Mn, 162 Dy, 52 Tr and 56 Fe.

[0209] Examples of suitable fluorescent labels include 152Eu labeling, fluorescein labeling, isothiocyanate labeling, rhodamine labeling, phycoerythrin labeling, phycocyanin labeling, allophycocyanin labeling, green fluorescent protein (GFP) labeling, o-phthalaldehyde labeling and fluorescamine labeling.Examples of suitable toxin labels include diphtheria toxin, ricin toxin and cholera toxin.

[0210] Examples of chemiluminescent labels include luminol labels, isoluminol labels, aromatic acridinium ester labels, imidazole labels, acridinium salt labels, oxalate labels, luciferin labels, luciferase labels, and aequorin labels. Examples of nuclear magnetic resonance contrast agents include heavy metal nuclei such as Gd, Mn, and iron.

[0211] The detection methods of the present technology can be used to detect immunoreactive DLL3 proteins in biological samples in vitro as well as in vivo. In vitro techniques for detecting immunoreactive DLL3 proteins include enzyme-linked immunosorbent assay (ELISA), Western blotting, immunoprecipitation, radioimmunoassay, and immunofluorescence. In addition, in vivo techniques for detecting immunoreactive DLL3 proteins include introducing labeled anti-DLL3 antibodies into a subject. For example, an anti-DLL3 antibody can be labeled with a radioactive marker, the presence and location of which in a subject can be detected by standard imaging techniques. In one embodiment, the biological sample contains DLL3 protein molecules from a test subject.

[0212] Immunoassays and Imaging. The anti-DLL3 antibodies of the present technology can be used to determine the level of immunoreactive DLL3 protein in biological samples (e.g., human plasma) using antibody-based techniques. For example, protein expression in tissues can be studied using classical immunohistological methods. Jalkanen, M. et al., J. Cell. Biol. 101:976-985, 1985; Jalkanen, M. et al., J. Cell. Biol. 105:3087-3096, 1987. Other antibody-based methods that can be used to detect protein gene expression include immunoassays such as enzyme-linked immunosorbent assays (ELISAs) and radioimmunoassays (RIAs). Suitable antibody assay labels are known in the art and include enzyme labels (such as glucose oxidase) and radioisotopes or other radioactive agents (such as iodine ( 125 I. 121 I. 131 I), carbon ( 14 C) Sulfur ( 35 S), tritium ( 3 H), Indium ( 111 In) and technetium ( 99mTc)) and fluorescent labels such as fluorescein, rhodamine, and green fluorescent protein (GFP), as well as biotin.

[0213] In addition to determining the level of immunoreactive DLL3 protein in a biological sample, the anti-DLL3 antibodies of the present technology can also be used for in vivo imaging of DLL3. Antibodies useful in this method include those detectable by X-ray radiography, NMR, or ESR. For X-ray radiography, suitable labels include radioisotopes, such as barium or cesium, which emit detectable radiation but are not significantly harmful to the subject. Suitable labels for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which can be incorporated into the anti-DLL3 antibody by labeling nutrients for the relevant scFv clone.

[0214] The cells have been treated with an appropriate detectable imaging moiety such as a radioisotope (e.g. 131 I. 111 In, 99 mTc, 18 F. 89 An anti-DLL3 antibody of the present technology labeled with a Zr, a radiopaque substance, or a material detectable by nuclear magnetic resonance (e.g., parenterally, subcutaneously, or intraperitoneally) is introduced into a subject. It will be understood in the art that the size of the subject and the imaging system used will determine the amount of imaging moiety required to produce a diagnostic image. In the case of a radioisotope moiety, for a human subject, the amount of radioactivity injected is typically between about 5 and 20 millicuries. 99m The labeled anti-DLL3 antibody will then accumulate in the cell location containing the specific target polypeptide. For example, the labeled anti-DLL3 antibody of the present technology will accumulate in cells and tissues in the subject where the DLL3 protein has been localized.

[0215] Thus, the present technology provides a method for diagnosing a medical condition, the method involving: (a) determining the expression of an immunoreactive DLL3 protein by measuring the binding of an anti-DLL3 antibody of the present technology in cells or body fluids of an individual; and (b) comparing the amount of immunoreactive DLL3 protein present in the sample with a standard reference, wherein an increase or decrease in the level of the immunoreactive DLL3 protein compared to the standard indicates a medical condition.

[0216] Affinity purification. The anti-DLL3 antibodies of the present technology can be used to purify immunoreactive DLL3 protein from a sample. In some embodiments, the antibody is immobilized on a solid support. Examples of such solid supports include plastics such as polycarbonates, complex carbohydrates such as agarose and sepharose, acrylic resins, and beads such as polyacrylamide and latex. Techniques for coupling antibodies to such solid supports are well known in the art (Weir et al., "Handbook of Experimental Immunology" 4th Edition, Blackwell Scientific Publications, Oxford, England, Chapter 10 (1986); Jacoby et al., Meth. Enzym. 34 Academic Press, NY (1974)).

[0217] The simplest method of combining antigen with antibody-support matrix is ​​to collect beads in a column and pass the antigen solution downward through the column. The efficiency of this method depends on the contact time between the immobilized antibody and the antigen, and the contact time can be extended by using a low flow rate. The immobilized antibody captures the antigen when the antigen flows through. Alternatively, the antigen can be contacted with the antibody support matrix in the following manner: the antigen solution is mixed with a support (e.g., beads) and rotated or shaken to achieve maximum contact between the antigen and the immobilized antibody. After the binding reaction is completed, the slurry is passed into the column to collect beads. The beads are washed with a suitable washing buffer solution, and then the pure or substantially pure antigen is eluted.

[0218] The antibody or polypeptide of interest can be conjugated to a solid support such as a bead. In addition, if desired, a first solid support such as a bead can also be conjugated to a second solid support (which can be a second bead or other support) by any suitable means, including those disclosed herein for conjugating a polypeptide to a support. Therefore, any conjugation methods and means disclosed herein for conjugating a polypeptide to a solid support can also be used to conjugate a first support to a second support, wherein the first and second solid supports can be the same or different.

[0219] Suitable linkers (which may be crosslinkers) for conjugating polypeptides to solid supports include a variety of agents that can react with functional groups present on the support surface or with the polypeptide or both. Reagents that can be used as crosslinkers include homobifunctional agents and particularly heterobifunctional agents. Useful bifunctional crosslinkers include, but are not limited to, N-SIAB, dimaleimide, DTNB, N-SATA, N-SPDP, SMCC, and 6-HYNIC. The crosslinker can be selected to provide a selectively cleavable bond between the polypeptide and the solid support. For example, a photolabile crosslinker such as 3-amino-(2-nitrophenyl) propionic acid can be used as a means of cleaving the polypeptide from the solid support. (Brown et al., Mol. Divers, pp. 4-12 (1995); Rothschild et al., Nucl. Acids Res., 24: 351-66 (1996); and U.S. Pat. No. 5,643,722). Other crosslinking agents are well known in the art. (See, e.g., Wong (1991), supra; and Hermanson (1996), supra).

[0220] Can pass through the covalent amide bond formed between the carboxyl functionalized beads and the amino terminus of the polypeptide, or conversely by the covalent amide bond formed between the amino functionalized beads and the carboxyl terminus of the polypeptide, the antibody or polypeptide is fixed on a solid support (such as beads). In addition, a difunctional trityl linker can be attached to the support via an amino resin through an amino group or a carboxyl group on the resin, such as a 4-nitrophenyl active ester attached to a resin (such as Wang resin). When using the difunctional trityl method, the solid support may need to be treated with a volatile acid (such as formic acid or trifluoroacetic acid) to ensure that the polypeptide is cut and can be removed. In this case, the polypeptide can be deposited on the bottom of the hole of the solid support or on the flat surface of the solid support as a plaque without beads. After adding the matrix solution, the polypeptide can be desorbed into the MS.

[0221] Hydrophobic trityl linkers can also be used as acid-labile linkers by cleaving the amino-linked trityl group from the polypeptide using a volatile acid or an appropriate matrix solution (e.g., a matrix solution containing 3-HPA). Acid instability can also be altered. For example, a trityl, monomethoxytrityl, dimethoxytrityl, or trimethoxytrityl group can be changed to a suitable para-substituted or more acid-labile tritylamine derivative of the polypeptide, i.e., a trityl ether bond and a tritylamine bond can be formed with the polypeptide. Thus, the polypeptide can be removed from the hydrophobic linker, for example, by destroying the hydrophobic attraction under acidic conditions or by cleaving the trityl ether bond or the tritylamine bond, including (if necessary) under typical MS conditions, where a matrix such as 3-HPA is used as the acid.

[0222] Orthogonal cleavable linkers can also be used to bind a first solid support (e.g., beads) to a second solid support, or can be used to bind a polypeptide of interest to a solid support. Using such linkers, a first solid support (e.g., beads) can be selectively cleaved from a second solid support without cleaving the polypeptide from the support; the polypeptide can then be cleaved from the beads at a later time. For example, a disulfide linker that can be cleaved using a reducing agent such as DTT can be used to bind the beads to a second solid support, and an acid-cleavable bifunctional trityl group can be used to fix the polypeptide to the support. As desired, the connection between the polypeptide and the solid support can be cleaved first, for example, to keep the connection between the first and second supports intact. The trityl linker can provide covalent or hydrophobic conjugation, and regardless of the nature of the conjugation, the trityl group is easily cleaved under acidic conditions.

[0223] For example, beads can be combined with a second support through a linking group, and a linking group with the following length and chemical properties can be selected, which promotes high-density binding of beads to solid supports or high-density binding of polypeptides to beads. Such linking groups can have, for example, a "tree-like" structure, thereby providing multiple functional groups for each attachment site on the solid support. Examples of such linking groups include polylysine, polyglutamic acid, penta-erythrole, and trihydroxyaminomethane.

[0224] Non-covalent binding association. Through non-covalent interactions, antibodies or polypeptides can be conjugated to a solid support, or a first solid support can also be conjugated to a second solid support. For example, magnetic beads made of ferromagnetic materials that can be magnetized can be attracted to a magnetic solid support and can be released from the support by removing the magnetic field. Alternatively, the solid support can have ionic or hydrophobic moieties, which can allow the ionic or hydrophobic moieties to interact with a polypeptide (e.g., a polypeptide containing an attached trityl group) or with a second solid support having a hydrophobic character, respectively.

[0225] The solid support may also have members of a specific binding pair and thus may be conjugated to a polypeptide containing a complementary binding moiety or to a second solid support. For example, beads coated with avidin or with streptavidin may be bound to a polypeptide in which a biotin moiety is incorporated, or to a second solid support coated with biotin or a biotin derivative such as iminobiotin.

[0226] It should be appreciated that any binding member disclosed herein or otherwise known in the art can be reversed. Thus, for example, biotin can be incorporated into a polypeptide or solid support, and conversely, avidin or other biotin binding moiety can be incorporated into a support or polypeptide, respectively. Other specific binding pairs contemplated for use herein include, but are not limited to, hormones and their receptors, enzymes and their substrates, nucleotide sequences and their complementary sequences, antibodies and their specifically interacting antigens, and other such pairs known to those skilled in the art. A. Diagnostic Uses of Anti-DLL3 Antibodies of the Present Technology

[0227] Overview. The anti-DLL3 antibodies of the present technology can be used in diagnostic methods. Thus, the present technology provides methods of diagnosing DLL3 activity in a subject using the antibodies. Such anti-DLL3 antibodies of the present technology can be selected so that they have any level of epitope binding specificity and very high binding affinity to the DLL3 protein. Generally speaking, the higher the binding affinity of the antibody, the more stringent washing conditions can be performed in the immunoassay to remove non-specifically bound material without removing the target polypeptide. Thus, the anti-DLL3 antibodies of the present technology that can be used in diagnostic assays typically have about 10 8 M -1 , 10 9 M -1 , 10 10 M -1 , 10 11 M -1 or 10 12 M -1 Furthermore, it is desirable that anti-DLL3 antibodies for use as diagnostic reagents have sufficient kinetic association rates to reach equilibrium under standard conditions within at least 12 h, at least five (5) h, or at least one (1) hour.

[0228] Anti-DLL3 antibodies can be used to detect immunoreactive DLL3 proteins in a variety of standard assay formats. Such formats include immunoprecipitation, Western blot, ELISA, radioimmunoassay, and immunometric assays. See Harlow and Lane, Antibodies, A Laboratory Manual (Cold Spring Harbor Publications, New York, 1988); U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,879,262; 4,034,074; 3,791,932; 3,817,837; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876. A biological sample may be obtained from any tissue or fluid of a subject. In certain embodiments, the subject is in an early stage of cancer. In one embodiment, the early stage of cancer is determined by the level or expression pattern of DLL3 protein in a sample obtained from the subject. In certain embodiments, the sample is selected from urine, blood, serum, plasma, saliva, amniotic fluid, cerebrospinal fluid (CSF), and biopsy body tissue.

[0229] Immunometric assays or sandwich assays are one form of diagnostic method of the present technology. See U.S. Pat. Nos. 4,376,110, 4,486,530, 5,914,241 and 5,965,375. Such assays use one antibody (e.g., an anti-DLL3 antibody or population of anti-DLL3 antibodies) fixed to a solid phase and another anti-DLL3 antibody or population of anti-DLL3 antibodies in solution. Typically, the solution anti-DLL3 antibody or population of anti-DLL3 antibodies is labeled. If a population of antibodies is used, the population may contain antibodies that bind specifically to different epitopes within the target polypeptide. Thus, the same population may be used for both solid phase and solution antibodies. If anti-DLL3 monoclonal antibodies are used, first and second DLL3 monoclonal antibodies with different binding specificities are used for the solid phase and solution phase. The solid phase (also referred to as "capture") and solution (also referred to as "detection") antibodies may be contacted with the target antigen in any order or simultaneously. If the solid phase antibody is contacted first, the assay is referred to as a forward assay. Conversely, if the solution antibody is contacted first, the assay is referred to as a reverse assay. If the target is contacted with both antibodies simultaneously, the assay is referred to as a simultaneous assay. After contacting the DLL3 protein with the anti-DLL3 antibody, the sample is incubated for a period of time, which typically varies from about 10 minutes to about 24 hours, and is typically about 1 hour. A washing step is then performed to remove components of the sample that are not specifically bound to the anti-DLL3 antibody used as a diagnostic reagent. When the solid phase antibody and the solution antibody are bound in separate steps, washing may be performed after either or both binding steps. After washing, binding is quantified, typically by detecting the label attached to the solid phase via binding of the labeled solution antibody. Typically for a given antibody pair or antibody population and given reaction conditions, a calibration curve is prepared from samples containing a known concentration of the target antigen. The concentration of immunoreactive DLL3 protein in the sample being tested is then read by interpolation from the calibration curve (i.e., standard curve). The analyte may be measured from the amount of labeled solution antibody bound at equilibrium or by kinetic measurement of the bound labeled solution antibody at a series of time points before equilibrium is reached. The slope of such a curve is a measure of the concentration of DLL3 protein in the sample.

[0230] Suitable supports for use in the above methods include, for example, nitrocellulose membranes, nylon membranes and derivatized nylon membranes, and also particles such as agarose, dextran-based gels, test strips, microparticles, microspheres, magnetic particles, test tubes, microtiter wells, SEPHADEX TM (Amersham Pharmacia Biotech, Piscataway, NJ) etc. Immobilization can be achieved by absorption or by covalent attachment. Optionally, the anti-DLL3 antibody can be linked to a linker molecule (such as biotin) to attach to a surface-bound linker (such as avidin).

[0231] In some embodiments, the present disclosure provides an anti-DLL3 antibody of the present technology conjugated to a diagnostic agent. The diagnostic agent can comprise a radioactive or non-radioactive label, a contrast agent (such as for magnetic resonance imaging, computed tomography, or ultrasound), and the radioactive label can be a gamma, beta, alpha, Auger electron, or positron emitting isotope. The diagnostic agent is a molecule that is administered conjugated to an antibody portion, i.e., an antibody or antibody fragment or subfragment, and can be used to diagnose or detect disease by localizing cells containing the antigen.

[0232] Useful diagnostic agents include, but are not limited to, radioisotopes, dyes (such as using biotin-streptavidin complexes), contrast agents, fluorescent compounds or molecules, and enhancers (such as paramagnetic ions) for magnetic resonance imaging (MRI). U.S. Patent No. 6,331,175 describes MRI technology and the preparation of antibodies conjugated to MRI enhancers, and is incorporated by reference in its entirety. In some embodiments, the diagnostic agent is selected from radioisotopes, enhancers for magnetic resonance imaging, and fluorescent compounds. In order to load radioactive metals or paramagnetic ions on the antibody component, it may be necessary to react it with a reagent having a long tail, to which a variety of chelating groups for binding ions are attached. This tail can be a polymer, such as polylysine, polysaccharides or other derivatized or derivatizable chains, and the polymer has a side group that can be combined with a chelating group, and the chelating group is, for example, ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), porphyrin, polyamines, crown ethers, bis-thiosemicarbazones, polyoximes, and similar groups known to be useful for this purpose. Chelates can be coupled to the antibodies of the present technology using standard chemical methods. Chelates are typically linked to antibodies via groups that are capable of forming bonds with the molecule with minimal loss of immunoreactivity and minimal aggregation and / or internal cross-linking. Other methods and reagents for conjugating chelates to antibodies are disclosed in U.S. Pat. No. 4,824,659. Particularly useful metal-chelate combinations include 2-benzyl-DTPA and its monomethyl and cyclohexyl analogs for use with diagnostic isotopes for radioimaging. When complexed with non-radioactive metals such as manganese, iron, and gadolinium, the same chelates can be used for MRI when used with the DLL3 antibodies of the present technology. B. Therapeutic Uses of Anti-DLL3 Antibodies of the Present Technology

[0233] The immunoglobulin-related compositions (e.g., antibodies or antigen-binding fragments thereof) of the present technology can be used to treat DLL3-related cancers. Such treatment can be used for patients identified as having pathologically high levels of DLL3 (e.g., patients diagnosed by the methods described herein) or patients diagnosed with a disease known to be associated with such pathological levels. In one aspect, the present disclosure provides a method for treating DLL3-related cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of an antibody (or antigen-binding fragment thereof) of the present technology. Examples of cancers that can be treated by the antibodies of the present technology include, but are not limited to, small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), pulmonary neuroendocrine carcinoma, extrapulmonary neuroendocrine carcinoma, and melanoma.

[0234] The immunoglobulin-related compositions of the present technology can be used in combination with other therapeutic agents that can be used to treat DLL3-related cancers. For example, the antibodies of the present technology can be administered alone, sequentially or simultaneously with at least one additional therapeutic agent, or conjugated with at least one additional therapeutic agent, wherein the at least one additional therapeutic agent is selected from marine-derived compounds (e.g., Aplysia 10, Auristatin, Tasedotine, Aplysia 15 or variants thereof, Monomethyl Auristatin E (MMAE), Monomethyl Auristatin F (MMAF)) (see Newman and Cragg, Mar Drugs. 2017 Apr; 15(4):99), vinca agents, anti-estrogen drugs, aromatase inhibitors, ovarian inhibitors, VEGF / VEGFR inhibitors, PARP inhibitors, cytostatic alkaloids, cytotoxic antibiotics, antimetabolites, endocrine / hormonal agents, bisphosphonate therapy agents, and targeted biological therapy agents (e.g., described in US 6306832, WO 2012007137, WO 2005000889, WO2010096603, etc.), alkylating agents, alkyl sulfonates, amanitin, aziridines, ethyleneimines and methylamylamines, polyacetyl, camptothecin, bryostatin, calistatin, CC-1065, cretoxin, tail sea pine, multicarmycin, eleutherobin, water banana alkaloid, sarcodictyin, spongistatin, nitrogen mustard, antibiotics, enediyne antibiotics, dynemicin, bisphosphonates, esperamicins, chromoprotein enediyne antibiotic chromophores, aclacinomycins, actinomycins, anthramycins, azoserine, bleomycins, actinomycins, carabicin, carminomycins, chromomycins, dactinomycin, daunorubicin, detoxibacin, 6-diazo-5-oxo-L-norleucine, Doxorubicin, epirubicin, esorubicin, idarubicin, mexilomycin, mitomycin, mycophenolic acid, nogamycin, olive mycin, peplomycin, potfiromycin, puromycin, triferric doxorubicin, rhodorubicin, streptozotocin, streptozotocin, tuberculocidin, ubenimex, zoloft, daunorubicin; antimetabolites, folic acid analogs, purine analogs, androgens, antiadreners, folic acid supplements such as frolinicacid, aceglucuronide, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, besbush ( bestrabucil), bisantrene, edatrexate, defofamine, colcemid, diazocone, elfornithine, elethonium, epothilone, etogluconate, gallium nitrate, hydroxyurea, lentinan, lonidamine, maytansinoids, mitoxantrone, mitoxantrone, mopidanmol, nitraerine, pentostatin, methamine, pirarubicin, losoxantrone, podophyllic acid, 2-ethylhydrazine, procarbazine, polysaccharide complex (JHS Natural Products, Oregon); razoxane; rhizoxin; sizoran; spirogermanamine; tricholomanic acid; triazoline quinone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, baculozolin A, and serpentin); urethane; vindesine; vemurafenib; dacarbazine; mannitol mustard; dibromomannitol; dibromodulanol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes; chloranbucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine, Vinorelbine; Noxol; Teniposide; Edatrexate; Daunorubicin; Aminopterin; Xeloda; Ibandronate; Irinotecan (Camptosar, CPT-11); Topoisomerase inhibitor RFS2000; Difluoromethylornithine; Retinoic acid; Capecitabine; Compretin; Leucovorin; Oxaliplatin; PKC-α, Raf, H-Ras, EGFR and VEGF-A inhibitors (which reduce cell proliferation), and pharmaceutically acceptable salts or solvates, acids or derivatives of any of the above. In some embodiments, the at least one additional therapeutic agent is a chemotherapeutic agent. Specific chemotherapeutic agents include, but are not limited to, cyclophosphamide, fluorouracil (or 5-fluorouracil or 5-FU), methotrexate, edatrexate (10-ethyl-10-deaza-aminopterin), thiotepa, carboplatin, cisplatin, taxanes, paclitaxel, protein-bound paclitaxel, docetaxel, vinorelbine, tamoxifen, raloxifene, toremifene, fulvestrant, gemcitabine, irinotecan, ixabepilone, temozolomide, topotecan, vincristine, vinblastine, eribulin, mutamycin, capecitabine, anastrozole, exemestane, Letrozole, leuprolide, abarelix, buserelin, goserelin, megestrol acetate, risedronate, pamidronate, ibandronate, alendronate, denosumab, zoledronate, trastuzumab, lapatinib, anthracyclines (e.g., daunorubicin and doxorubicin), bevacizumab, oxaliplatin, melphalan, etoposide, nitrogen mustard, bleomycin, microtubule poisons, annonaceous acetone, auristatins, maytansinoids, tubulysins, calicheamicins, duocarmycins, benzodiazepines, camptothecins, or a combination thereof.

[0235] Other compatible anticancer agents include commercially available or clinically available compounds such as erlotinib ( Genentech / OSIPharm.), docetaxel ( Sanofi-Aventis), 5-FU (fluorouracil, 5-fluorouracil, CAS No. 51-21-8), PD-0325901 (CAS No. 391210-10-9, Pfizer), cisplatin (cisplatin (II), CAS No. 15663-27-1), carboplatin (CAS No. 41575-94-4), paclitaxel ( Bristol-Myers Squibb Oncology, Princeton, NJ), trastuzumab ( Genentech), temozolomide (4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide, CAS No. 85622-93-1, Schering Plough), tamoxifen ((Z)-2-[4-(l,2-diphenylbut-l-enyl)phenoxy]-N,N-dimethylethylamine, ) and doxorubicin ( Other commercially available or clinically available anticancer agents include bortezomib ( Millennium Pharm.), Sutent ( SU11248, Pfizer), letrozole ( Novartis), imatinib mesylate ( Novartis), XL-518 (Mek inhibitor, Exelixis, WO 2007 / 044515), ARRY-886 (Mek inhibitor, AZD6244, Array BioPharma, AstraZeneca), SF-1126 (PI3K inhibitor, Semafore Pharmaceuticals), BEZ-235 (PI3K inhibitor, Novartis), XL-147 (PI3K inhibitor, Exelixis), PTK787 / ZK 222584 (Novartis), Fulvestrant ( AstraZeneca), leucovorin (folinic acid), rapamycin (sirolimus, Wyeth), lapatinib ( GSK572016, Glaxo Smith Kline), Lonafarnib (SARAS AR TM , SCH 66336, Schering Plough), sorafenib ( BAY43-9006, BayerLabs), gefitinib ( AstraZeneca), irinotecan ( CPT-11, Pfizer), Tipifarnib (ZARNESTRA TM , Johnson&Johnson), ABRAXANE TM (without hydrogenated castor oil), albumin-engineered paclitaxel nanoparticle formulation (American Pharmaceutical Partners, Schaumberg, II), vandetanib (rINN, ZD6474, , AstraZeneca), chlorambucil, AG1478, AG1571 (SU 5271; Sugen), sirolimus ( Wyeth), pazopanib (GlaxoSmithKline), cyclophosphamide ( Telik), thiotepa, and cyclophosphamide ( ); Vinorelbine ( ); Capecitabine ( Roche), tamoxifen (including Tamoxifen citrate, (Toremifene citrate) (Megestrol acetate), (exemestane; Pfizer), formestane, fadrozole, (vorozole), and (anastrozole; AstraZeneca); darafenamide ( , GlaxoSmithKline); dasatinib ( Bristol-Myers Squibb; Trametinib ( GlaxoSmithKline; Nilotinib ( Novartis), troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); antisense oligonucleotides, ribozymes, such as VEGF expression inhibitors and HER2 expression inhibitors; vaccines, Topoisomerase 1 inhibitors; Vinorelbine and esperamicin and pharmaceutically acceptable salts, acids or derivatives of any one of the above.

[0236] The composition of the present technology can be optionally administered to a subject in need thereof in the form of a single bolus injection. Alternatively, the dosing regimen can include multiple administrations at different times after the tumor appears.

[0237] Administration can be by any suitable route, including oral, intranasal, parenteral (intravenous, intramuscular, intraperitoneal or subcutaneous), rectal, intracranial, intratumoral, intrathecal or topical. Administration includes self-administration and administration by another person. It is also understood that the various treatments of medical conditions as described herein are intended to mean "substantially," which includes complete treatment but also less than complete treatment, and in which some biologically or medically relevant results are achieved.

[0238] In some embodiments, the antibodies of the present technology constitute a pharmaceutical formulation, which can be administered to a subject in need thereof in one or more doses. The dosage regimen can be adjusted to provide a desired response (e.g., a therapeutic response).

[0239] Typically, the effective amount of the antibody composition of the present invention technology sufficient to achieve a therapeutic effect is in the range of about 0.000001 mg per kilogram of body weight per day to about 10,000 mg per kilogram of body weight per day. Typically, the dosage range is from about 0.0001 mg / kg body weight / day to about 100 mg / kg body weight / day. For the administration of anti-DLL3 antibodies, the dosage range is 0.0001 to 100 mg / kg subject body weight per week, every two weeks or every three weeks, and more typically 0.01 to 5 mg / kg subject body weight. For example, the dosage can be 1 mg / kg body weight or 10 mg / kg body weight per week, every two weeks or every three weeks, or in the range of 1-10 mg / kg per week, every two weeks or every three weeks. In one embodiment, the single dose range of the antibody is 0.1-10,000 micrograms / kg body weight. In one embodiment, the antibody concentration in the carrier ranges from 0.2 to 2000 micrograms per milliliter delivered. Exemplary treatment regimens require administration once every two weeks or once a month or once every 3 to 6 months. Anti-DLL3 antibodies can be administered on multiple occasions. The intervals between individual doses can be hourly, daily, weekly, monthly or yearly. Intervals can also be irregular as indicated by measuring blood levels of antibodies in the subject. In some methods, the dose is adjusted to achieve the following serum antibody concentrations in the subject: about 75 μg / mL to about 125 μg / mL, 100 μg / mL to about 150 μg / mL, about 125 μg / mL to about 175 μg / mL or about 150 μg / mL to about 200 μg / mL. Alternatively, the anti-DLL3 antibody can be administered as a sustained release formulation, in which case less frequent administration is required. The dose and frequency vary depending on the half-life of the antibody in the subject. The dose and frequency of administration can vary depending on whether the treatment is preventive or therapeutic. In preventive applications, relatively low doses are administered at relatively infrequent intervals over a long period of time. In therapeutic applications, it is sometimes necessary to administer relatively high doses at relatively short intervals until the progression of the disease is reduced or terminated, or until the subject shows partial or complete improvement in symptoms of the disease. Thereafter, the patient may be administered a prophylactic regimen.

[0240] In another aspect, the disclosure provides a method for detecting a tumor in a subject in vivo, the method comprising (a) administering to the subject an effective amount of an antibody (or antigen-binding fragment thereof) of the present technology, wherein the antibody is configured to localize to a tumor expressing DLL3 and is labeled with a radioactive isotope; and (b) detecting the presence of a tumor in the subject by detecting a level of radioactivity emitted by the antibody that is higher than a reference value. In some embodiments, the reference value is expressed as injected dose / gram (%ID / g). The reference value can be calculated by measuring the level of radioactivity present in non-tumor (normal) tissues and calculating the average radioactivity level ± standard deviation present in non-tumor (normal) tissues. In some embodiments, the ratio of radioactivity levels between tumor and normal tissue is about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, or 100:1.

[0241] In some embodiments, the subject is diagnosed with or suspected of having cancer.The level of radioactivity emitted by the antibody can be detected using positron emission tomography or single photon emission computed tomography.

[0242] Additionally or alternatively, in some embodiments, the method further comprises administering to the subject an effective amount of an immunoconjugate comprising an antibody of the present technology conjugated to a radionuclide. In some embodiments, the radionuclide is an alpha particle emitting isotope, a beta particle emitting isotope, an Auger emitter, or any combination thereof. Examples of beta particle emitting isotopes include 86 Y. 90 Y. 89 Sr. 165 Dy, 186 Re, 188 Re, 177 Lu and 67 Cu. Examples of alpha-emitting isotopes include 213 Bi, 211 At 225 Ac, 152 Dy, 212 Bi, 223 Ra, 219 Rn, 215 Po, 211 Bi, 221 Fr. 217 At and 255Fm. Examples of Auger emitters include 111 In, 67 Ga, 51 Cr, 58 Co. 99m Tc, 103m Rh, 195m Pt, 119 Sb, 161 Ho, 189m Os, 192 Ir, 201 Tland 203 Pb. In some embodiments of the method, non-specific FcR-dependent binding in normal tissues is eliminated or reduced (e.g., via the N297A mutation in the Fc region, which results in deglycosylation). The therapeutic effectiveness of this immunoconjugate can be determined by calculating the area under the curve (AUC) tumor: AUC normal tissue ratio. In some embodiments, the AUC tumor: AUC normal tissue ratio of the immunoconjugate is about 2: 1, 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 15: 1, 20: 1, 25: 1, 30: 1, 35: 1, 40: 1, 45: 1, 50: 1, 55: 1, 60: 1, 65: 1, 70: 1, 75: 1, 80: 1, 85: 1, 90: 1, 95: 1 or 100: 1.

[0243] Toxicity. Optimally, an effective amount (e.g., dose) of an anti-DLL3 antibody described herein will provide therapeutic benefit without causing substantial toxicity to the subject. The toxicity of the anti-DLL3 antibodies described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, such as by measuring the LD 50 (dose lethal to 50% of the population) or LD 100 The therapeutic index is determined by the dose ratio between toxic and therapeutic effects. The data obtained from these cell culture assays and animal studies can be used to formulate a dosage range that is nontoxic to humans. The dosage of the anti-DLL3 antibodies described herein lies within a range of circulating concentrations that include an effective dose with little or no toxicity. The dosage can vary within this range depending on the dosage form employed and the route of administration utilized. The exact formulation, route of administration, and dosage can be chosen by the individual physician according to the subject's circumstances. See, e.g., Fingl et al., The Pharmacological Basis of Therapeutics, Chapter 1 (1975).

[0244] Formulation of pharmaceutical compositions. According to the methods of the present technology, an anti-DLL3 antibody can be incorporated into a pharmaceutical composition suitable for administration. The pharmaceutical composition typically comprises a recombinant or substantially purified antibody and a pharmaceutically acceptable carrier in a form suitable for administration to a subject. The pharmaceutically acceptable carrier depends in part on the specific composition being administered, as well as on the specific method used to administer the composition. Thus, there are a variety of suitable formulations of pharmaceutical compositions for administering antibody compositions (see, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA 18th edition, 1990). The pharmaceutical composition is typically formulated to be sterile, substantially isotonic, and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.

[0245] The terms "pharmaceutically acceptable", "physiologically tolerable" and grammatical variants thereof, when they refer to compositions, carriers, diluents and agents, are used interchangeably and indicate that the material can be administered to or onto a subject without producing undesirable physiological effects to the extent that would prohibit the administration of the composition. For example, "pharmaceutically acceptable excipient" means an excipient that can be used to prepare a pharmaceutical composition that is generally safe, non-toxic and desirable, and includes excipients that are acceptable for veterinary and human pharmaceutical use. Such excipients can be solid, liquid, semisolid, or, in the case of aerosol compositions, gas. "Pharmaceutically acceptable salts and esters" means salts and esters that are pharmaceutically acceptable and have the desired pharmacological properties. Such salts include salts that can be formed when acidic protons present in the composition are able to react with inorganic or organic bases. Suitable inorganic salts include those formed with alkali metals such as sodium and potassium, magnesium, calcium and aluminum. Suitable organic salts include those formed with organic bases, such as amine bases, for example, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. Such salts also include acid addition salts formed with inorganic acids, such as hydrochloric acid and hydrobromic acid, and organic acids, such as acetic acid, citric acid, maleic acid, and alkanesulfonic and aromatic sulfonic acids, such as methanesulfonic acid and benzenesulfonic acid. Pharmaceutically acceptable esters include esters formed with carboxyl, sulfonyloxy, and phosphonooxy groups present in the anti-DLL3 antibody, such as C 1-6Alkyl esters. When two acidic groups are present, the pharmaceutically acceptable salt or ester may be a monoacid monosalt or ester or a disalt or ester; and similarly, when more than two acidic groups are present, some or all of such groups may be salified or esterified. The anti-DLL3 antibodies named in this technology may exist in unsalted or unesterified form, or in salified and / or esterified form, and the naming of such anti-DLL3 antibodies is intended to include the original (unsalted and unesterified) compound and its pharmaceutically acceptable salts and esters. In addition, certain embodiments of the present technology may exist in more than one stereoisomer form, and the naming of such anti-DLL3 antibodies is intended to include all single stereoisomers and all mixtures of such stereoisomers (whether racemic or otherwise). It is not difficult for one of ordinary skill in the art to determine the appropriate timing, sequence, and dosage for administering a particular drug and composition of the present technology.

[0246] Examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and nonaqueous vehicles, such as fixed oils, may also be used. The use of such media and compounds for pharmaceutically active substances is well known in the art. Unless any conventional media or compound is incompatible with the anti-DLL3 antibody, its use in the composition is contemplated. Supplementary active compounds may also be incorporated into the composition.

[0247] The pharmaceutical compositions of the present technology are formulated to be compatible with their intended route of administration. The anti-DLL3 antibody compositions of the present technology can be administered parenterally, topically, intravenously, orally, subcutaneously, intraarterially, intradermally, transdermally, rectally, intracranially, intrathecally, intraperitoneally, intranasally; or intramuscularly, or as an inhalant. The anti-DLL3 antibodies can be administered optionally in combination with other drugs that are at least partially effective in treating various DLL3-related cancers.

[0248] Solutions or suspensions for parenteral, intradermal or subcutaneous administration may include the following components: sterile diluents, such as water for injection, saline solution, fixed oils, polyethylene glycol, glycerol, propylene glycol or other synthetic solvents; antibacterial compounds, such as benzyl alcohol or methyl parabens; antioxidants, such as ascorbic acid or sodium bisulfite; chelating compounds, such as ethylenediaminetetraacetic acid (EDTA); buffers (such as acetates, citrates or phosphates), and compounds for adjusting tonicity (such as sodium chloride or dextrose). pH can be adjusted with acids or bases (such as hydrochloric acid or sodium hydroxide). Parenteral preparations can be packaged in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0249] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL TM (BASF, Parsippany, New Jersey) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that it is easy to inject. The composition must be stable under manufacturing and storage conditions, and its preservation must be resistant to the contaminating effects of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium, which contains, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol and liquid polyethylene glycol, etc.) and suitable mixtures thereof. For example, by using a coating such as lecithin, by maintaining the desired particle size in the case of a dispersion, and by using a surfactant, appropriate fluidity can be maintained. Preventing the effects of microorganisms can be achieved by a variety of antibacterial and antifungal compounds (e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc.). In many cases, it is desirable to include isotonic compounds in the composition, such as sugars, polyols (e.g., mannitol, sorbitol), sodium chloride. Extended absorption of injectable compositions can be achieved by including compounds that delay absorption in the composition, such as aluminum monostearate and gelatin.

[0250] Sterile injectable solutions can be prepared by incorporating the anti-DLL3 antibody of the present technology in the desired amount into an appropriate solvent optionally having one or a combination of the ingredients listed above, followed by filtration sterilization. Typically, dispersions are prepared by incorporating the anti-DLL3 antibody into a sterile vehicle containing a basic dispersion medium and the desired other ingredients from those listed above. In the case of sterile powders for preparing sterile injectable solutions, the preparation methods are vacuum drying and freeze drying, which produce a powder of the active ingredient and any additional desired ingredients from a previously sterile-filtered solution. The antibodies of the present technology can be administered in the form of a depot injection or implant formulation, which can be formulated in a manner that allows for sustained or pulsatile release of the active ingredient.

[0251] Oral compositions typically include an inert diluent or edible carrier. They can be encapsulated in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, anti-DLL3 antibodies can be incorporated with excipients and used in the form of tablets, lozenges or capsules. Oral compositions can also be prepared using a fluid carrier used as a mouthwash, where the compound in the fluid carrier is orally administered and rinsed and spit out or swallowed. Pharmaceutically compatible binding compounds and / or auxiliary materials can be included as part of the composition. Tablets, pills, capsules, lozenges, etc. may contain any of the following ingredients or compounds of similar nature: binders, such as microcrystalline cellulose, tragacanth or gelatin; excipients, such as starch or lactose, disintegrating compounds, such as alginic acid, Primogel or corn starch; lubricants, such as magnesium stearate or Sterotes; glidants, such as colloidal silica; sweetening compounds, such as sucrose or saccharin; or flavoring compounds, such as mint, methyl salicylate or orange flavor.

[0252] For administration by inhalation, the anti-DLL3 antibody can be delivered in the form of an aerosol spray from a pressured container or dispenser which contains a suitable propellant, eg, a gas such as carbon dioxide, or a nebulizer.

[0253] Systemic administration can also be performed by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the anti-DLL3 antibody is formulated into an ointment, salves, gel, or cream as generally known in the art.

[0254] Anti-DLL3 antibodies can also be prepared as pharmaceutical compositions for rectal delivery in the form of suppositories (eg, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas.

[0255] In one embodiment, the anti-DLL3 antibody is prepared with a carrier that prevents rapid clearance of the anti-DLL3 antibody from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid may be used. Methods for preparing such formulations will be clear to those skilled in the art. The materials can also be commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, such as those described in U.S. Pat. No. 4,522,811. C. Kit

[0256] The present technology provides a kit for detecting and / or treating DLL3-related cancers, the kit comprising at least one immunoglobulin-related composition of the present technology (e.g., any antibody or antigen-binding fragment described herein) or a functional variant thereof (e.g., a substitution variant). Optionally, the above components of the kit of the present technology are packaged in a suitable container and labeled for diagnosis and / or treatment of DLL3-related cancers. The above components can be stored in a unit container or a multi-dose container (e.g., a sealed ampoule, vial, bottle, syringe, and test tube) as an aqueous solution (preferably a sterile solution) or as a lyophilized (preferably sterile) formulation for reconstitution. The kit may further comprise a second container containing a diluent suitable for diluting the pharmaceutical composition to a larger volume. Suitable diluents include, but are not limited to, pharmaceutically acceptable excipients and saline solutions of the pharmaceutical composition. In addition, the kit may comprise instructions for diluting the pharmaceutical composition and / or instructions for administering the diluted or undiluted pharmaceutical composition. The container can be made of a variety of materials (such as glass or plastic) and can have a sterile access port (for example, the container can be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic needle). The kit can also include more containers containing pharmaceutically acceptable buffers, such as phosphate-buffered saline, Ringer's solution, and dextrose solution. The kit can also include other materials that are desirable from a commercial and user perspective, including other buffers, diluents, filters, needles, syringes, culture media for one or more suitable hosts. The kit can optionally include instructions that are typically included in the commercial packaging of the therapeutic or diagnostic product, the instructions containing information about, for example, the indications, usage, dosage, manufacture, administration, contraindications, and / or warnings for the use of such therapeutic or diagnostic products.

[0257] The kit can be used to detect the presence of immunoreactive DLL3 in a biological sample, such as any body fluid, including but not limited to, for example, serum, plasma, lymph, cystic fluid, urine, feces, cerebrospinal fluid, ascites, or blood, and including a biopsy sample of a body tissue. For example, the kit can include: one or more humanized, chimeric, or bispecific anti-DLL3 antibodies (or antigen-binding fragments thereof) of the present technology that are capable of binding DLL3 in a biological sample; a device for determining the amount of DLL3 in a sample; and a device for comparing the amount of immunoreactive DLL3 in a sample to a standard. The one or more anti-DLL3 antibodies can be labeled. The kit components (e.g., reagents) can be packaged in a suitable container. The kit can further include instructions for using the kit to detect immunoreactive DLL3.

[0258] For antibody-based kits, the kit can include, for example, 1) a first antibody, such as a humanized, chimeric or bispecific DLL3 antibody (or antigen-binding fragment thereof) of the present technology, attached to a solid support, which first antibody binds to a DLL3 polypeptide; and, optionally; 2) a second, different antibody that binds to a DLL3 polypeptide or to the first antibody and is conjugated to a detectable label.

[0259] The kit may also contain, for example, a buffer, a preservative, or a protein stabilizer. The kit may also contain other components required for detection of the detectable marker, such as an enzyme or a substrate. The kit may also contain a control sample or a series of control samples, which can be assayed and compared to the test sample. Each component of the kit may be enclosed in a separate container, and all of the different containers may be placed in a single package together with instructions for interpreting the results of assays performed using the kit. The kit of the present technology may contain a written product on or in the kit container. The written product describes how to use the reagents contained in the kit, for example, for detecting DLL3 polypeptides in vitro or in vivo, or for treating DLL3-related cancers in subjects in need thereof. In certain embodiments, the reagents may be used according to the methods of the present technology. Example

[0260] The present technology is further illustrated by the following examples, which should not be construed as limiting in any way.The following examples demonstrate the preparation, characterization, and use of illustrative anti-DLL3 antibodies of the present technology. Example 1: Production of monoclonal antibodies

[0261] The extracellular domain (ECD) of DLL3 (GenBank Accession No. Q9NY J7-1) corresponding to amino acids Ala27-Ala479 with a C-terminal 6×His tag produced in HEK293T cells stably expressing full-length DLL3 was used as an immunogen. Ablexis AlivaMAbκ mice (Ablexis, San Diego, CA) carrying a human immunoglobulin repertoire were immunized with soluble DLL3-ECD or stable cells over a 3-week period according to standard immunization techniques. Splenocytes and draining lymph node cells from mice with high serum titers specific for DLL3 were harvested and fused with mouse myeloma cells using electrofusion to generate hybridomas. These hybridomas were then screened for the presence of antibodies that specifically bound to soluble DLL3-ECD by ELISA and to full-length DLL3 protein by stably expressing 293 cells versus parental 293 cells by flow cytometry. Hybridomas were selected for further studies by ranking the staining intensity of 293DLL3 transfectants in flow cytometry and performing 4°C / 37°C staining as described below. Example 2: 4 / 37 internalization assay using monoclonal antibodies 6-G23-F, 2-C8-A, 7-I1-B and 10-018-A

[0262] The ability of four monoclonal antibodies (6-G23-F, 2-C8-A, 7-I1-B, and 10-O18-A) to internalize DLL3 was compared by comparing staining at 4°C and at 37°C. The reference monoclonal antibody SC16 (known to be internalized via DLL3 and to have ADC activity and previously reported in the literature) was used as a positive control for internalization. Exponentially growing NCI-H82 cells were harvested with trypsin / EDTA, washed once in RPMI containing 10% fetal calf serum (FCS), and plated at 2×10 7 cells / ml were resuspended in DMEM supplemented with 10% FCS. 100 μl (2×10 6 Cells) were added to a U-bottom 96-well plate. Test monoclonal antibodies (6-G23-F, 2-C8-A, 7-I1-B, or 10-O18-A) or reference monoclonal antibodies were added to separate wells to give a final concentration of 10 μg / ml in duplicate plates. Both plates were kept at 4°C for 30 minutes, then both plates were washed twice with cold RPMI supplemented with 10% FCS and resuspended in RPMI supplemented with 10% FCS. One plate was kept at 4°C (control plate) and the other plate was kept at 37°C in CO 2 Incubate the test plate in an incubator at 37°C in a CO 2After incubation in an incubator and incubation of the control plate at 4°C for 4 hours, the cells were washed 3 times with cold wash buffer (PBS containing 0.5% BSA) at 4°C. The sample was then resuspended in cold wash buffer + R-phycoerythrin-AffiniPure F(ab')2 fragment goat anti-mouse IgG (Jackson 115-116-071) at a final concentration of 7 μg / ml in wash buffer. After incubation at 4°C for 30 minutes, the cells were washed three times in cold wash buffer and fixed in PBS 0.5% paraformaldehyde and analyzed by flow cytometry within 48 hours. The MFI obtained by the control plate (which was incubated with the antibody at 4°C) was divided by the mean fluorescence intensity (MFI) ratio calculated from the corresponding MFI obtained from the experimental plate (which was incubated with the antibody at 37°C) as a relative measure of internalization. High values ​​indicate greater internalization. As shown in the table below, all mAbs (6-G23-F, 2-C8-A, 7-I1-B, and 10-018-A) were able to internalize and bind DLL3, but not to the extent of the reference mAb. clone MFI Ratio 6-G23-F 1.67 2-C8-A 1.76 7-I1-B 1.68 10-O18-A 1.56 Reference monoclonal antibodies 2.66 Mouse IgG1 1.28

[0263] These results demonstrate that the immunoglobulin-related compositions of the present technology undergo internalization via binding to DLL3. Therefore, the immunoglobulin-related compositions disclosed herein can be used to deliver therapeutic agents to DLL3-positive cancer cells. Example 3: Quenched internalization assay of monoclonal antibodies 6-G23-F, 2-C8-A, 7-I1-B and 10-018-A.

[0264] In order to sort monoclonal antibodies with respect to internalization, a quenching internalization assay was used. This method reflects internalization and entry into the endosomal / lysosomal pathway. Goat anti-mouse IgG1 F (ab) (Jackson Immunoresearch 115-007-185) was double labeled with Dy light Dy650 NHS ester (Thermofisher 02206) and LICOR IRDye QC1 NHS ester (LICOR 929-7030) (the double labeled antibody is referred to herein as "F (ab) Dy650-QC1"). The principle of this assay is as follows: F (ab) Dy650-QC1 does not fluoresce because the Dy light Dy650 fluorescence is quenched by IRDye QC1. However, after internalization, F (ab) Dy650-QC1 is degraded via the endosomal / lysosomal pathway, and the resulting IRDye QC1 release makes it possible to observe the fluorescence of Dy light Dy650. Therefore, the Dy light Dy650 fluorescence signal was used as a measure of internalization via lysosomes. Briefly, exponentially growing NCI-H82 cells were harvested with trypsin / EDTA, washed once in growth medium RPMI supplemented with 10% FCS, and resuspended in growth medium, and 1.25 x 10 6 cells (80 μl). Monoclonal DLL3 antibody at a concentration of 200 μg / ml was mixed with goat anti-mouse IgG1 Dy650 QC1 at 200 μg / ml for 20 minutes at room temperature, and 20 μl of the mixture was added to the cells. After incubation at 4°C for 30 minutes, the cells were washed twice with growth medium, resuspended in growth medium and transferred to 37°C CO 2 The cells were then washed twice with ice-cold PBS containing 0.5% BSA and analyzed by flow cytometry, and the mean fluorescence intensity was determined. The mean fluorescence intensity of the control reference monoclonal was set to 100% internalization. As shown in the table below, all four monoclonal antibodies exhibited internalization and entry into the endosomal / lysosomal pathway. clone Dy light Dy658 fluorescence (% of reference monoclonal antibody) 6-G23-F (10 μg / ml) 76.5 7-I1-B (10 μg / ml) 70.1 2-C8-A (10 μg / ml) 62.9 10-O18-A (10 μg / ml) 62.2 Isotype Control 20

[0265] These results demonstrate that the immunoglobulin-related compositions of the present technology undergo internalization via binding to DLL3 and enter the phagosomal / lysosomal compartment of the cell. Therefore, the immunoglobulin-related compositions disclosed herein can be used to deliver therapeutic agents to DLL3-positive cancer cells. Example 4: Fab ZAP assay of anti-DLL3 monoclonal antibody panel.

[0266] Fab ZAP assay is used as another method to measure internalization. Fab ZAP assay measures the delivery of toxin to cells via internalization of anti-DLL3 monoclonal antibodies. Fab ZAP assay uses saporin toxin-conjugated F(ab) anti-mouse heavy and light chains to label monoclonal antibodies with toxins. Anti-DLL3 monoclonal antibody panels were characterized according to the Fab ZAP assay protocol using a kit from Advanced Targeting Systems. Briefly, exponentially growing NCI-H82 cells were harvested with trypsin / EDTA, washed once with RMPI supplemented with 10% FCS, and plated at 5000 cells / well on 96-well white solid plates in 100 μl RPMI supplemented with 10% FCS. The next day, 25 μl of purified monoclonal antibodies (G23-F, 2-C8-A, 7-I1-B or 10-O18-A) or reference monoclonal antibodies were added at a starting concentration of 10 μg / ml, and three consecutive dilutions were performed. Saponin-conjugated F(ab) anti-mouse Ig HL (Fab ZAP) was added in 25 μl to give a final concentration of 4.4 nM. After 3-4 days, the same volume of Cell Titre Glow (Promega G7571) was added to the plate, which was shaken on an orbital shaker for 2 minutes and after another 10 minutes at room temperature, the luminescence was read using a plate reader. All monoclonal antibodies were tested to full titration to negate the prozone effect. Figure 1 As shown in the table below, all monoclonal antibodies exhibited cytotoxic activity comparable to the reference monoclonal antibody. In other experiments with these monoclonal antibodies, the mouse IgG1 control monoclonal antibody did not exhibit cytotoxic activity. Therefore, these results demonstrate that the cytotoxic activity is mediated by recognition of DLL3 rather than through FcR.

[0267] These results demonstrate that the immunoglobulin-related compositions of the present technology can deliver therapeutic agents to tumors that express DLL3 on their cell surfaces. Therefore, the immunoglobulin-related compositions disclosed herein can be used to deliver therapeutic agents to DLL3-positive cancer cells. Example 5: Epitope binning of the anti-DLL3 monoclonal antibody panel.

[0268] exist Array surface plasmon resonance (SPR) assay platform ( Purified anti-DLL3 monoclonal antibodies and reference monoclonal antibodies were subjected to paired epitope binning on a 100nm HPLC-MS / ... Monoclonal Table box element 10-O18-A 1 7-I1-B 2 2-C8-A 2 6-G23-F 3

[0269] These results demonstrate that the immunoglobulin-related compositions of the present technology bind to three different epitopes present in the DLL3 protein. Therefore, the immunoglobulin-related compositions disclosed herein can be used in combination with each other to deliver multiple therapeutic agents to tumor cells expressing DLL3. Example 6: Affinity measurements.

[0270] The binding affinity of four monoclonal antibodies (6-G23-F, 2-C8-A, 7-I1-B and 10-O18-A) was determined by biolayer interferometry (BLI) using an Octet HTX instrument at 25°C using PBS 0.1% BSA 0.02% Tween 20 as binding buffer and 10mM glycine (pH 1.7) as regeneration buffer. The four purified monoclonal antibodies (5 μg / mL each) were loaded onto the anti-mouse Fc sensor. The loaded sensor was immersed in a serial dilution of recombinant human DLL3 protein (amino acids Ala27-Ala479, catalog number 9749-DL, R&D Systems) with a starting concentration of 200nM and 7 serial 1:3 dilutions. Figure 2A-2D As shown, binding is concentration-dependent. The dissociation constant (K) was calculated using a monovalent (1:1) binding model. D ).like Figure 2E As shown, all monoclonal antibodies had affinities in the subnanomolar range. Figure 7 It was shown that 6-G23-F, 10-018-A, and 2-C8-A monoclonal antibodies (mAbs) selectively bind to DLL3, but not to DLL1 or DLL4. 7-I1-B mAb binds to both DLL3 and DLL4, but not DLL1.

[0271] These results demonstrate that the immunoglobulin-related compositions of the present technology specifically bind to DLL3 with high affinity. Therefore, the immunoglobulin-related compositions of the present technology can be used in methods for detecting DLL3 protein in biological samples. Example 7: Binding of monoclonal antibodies to transfected and primary cells.

[0272] Four monoclonal antibodies (6-G23-F, 2-C8-A, 7-I1-B and 10-O18-A) were tested for their ability to bind to mouse and cynomolgus monkey DLL3 as well as endogenous human DLL3 by flow cytometry. To this end, HEK293 cells were transfected with plasmid DNA encoding full-length human, mouse or cynomolgus monkey DLL3 and used for the experiments. Briefly, 10 μg / ml of 1 ... 6 Transfected HEK293 cells or NCI-H82 primary cells were added to the wells of a 96-well U-bottom plate and purified monoclonals were added at 10 μg / ml. After incubation at 4°C for 30 minutes, cells were washed 3 times in FACS buffer and incubated with PE-labeled F(ab)2 anti-mouse IgG H and L phase 2. After incubation at 4°C for an additional 30 minutes, cells were washed three times in FACS buffer and analyzed on a flow cytometer. Data are presented as the ratio of the mean fluorescence intensity of the monoclonals divided by the background staining of phase 2. As shown in the table below, all monoclonal antibodies cross-reacted with cynomolgus monkey DLL3 and detected endogenous DLL3 on NCI H82 cells, but only 6-G23-F and 7-I1-B bound to mouse DLL3.

[0273] These results demonstrate that the immunoglobulin-related compositions of the present technology can be used in methods for detecting DLL3 protein in biological samples. Example 8: Sequencing.

[0274] The variable heavy chain and variable light chain of four kinds of monoclonal antibodies are separated from the corresponding hybridomas of 7-I1-B, 6-G23-F, 2-C8-A and 10-O18-A by RACE (rapid amplification of cDNA ends). RNA is isolated from the hybridoma of cracking using RNAEasy test kit (Qiagen). Isolation of mRNA is used for cDNA synthesis, and RACE test kit is used to generate PCR product. Then PCR product is cloned in TOPO vector, PCR amplification is carried out, and gel separation is used for sequencing subsequently. Heavy chain variable domain (V H ) and the light chain variable domain (V L ) are shown in the following table and Figure 3A - Figure 3D (7-I1-B), Figure 4A- Figure 4D (2-C8-A), Figure 5A - Figure 5D (10-O18-A) and Fig. 6A - Figure 6D (6-G23-F). Example 9: Treatment of NCI-H209 xenografts.

[0275] Eight-week-old female athymic nude mice will be used in this study. NCI-H209 tumor cells will be grown to mid-log phase in RPMI containing 10% fetal calf serum (FCS). Cells will be cultured in tissue culture flasks at 37°C in 5% CO 2 The mice were cultured in a humidified incubator with an atmosphere of 95% air. 5×10 cells in 50% Matrigel in a total volume of 0.2 ml were implanted subcutaneously on the right flank of the mice. 6 NCI-H209 tumor cells. Eight days after inoculation, when the tumor reached approximately 150 mm 3 The mice were randomly divided into groups when the mean tumor volume was . The mice were injected intraperitoneally with human IgG1 (1 or 10 mg / kg; n = 5-15 mice) as a negative control or one or more antibody-drug conjugates of 6-G23-F, 2-C8-A, 7-I1-B and 10-O18-A (1 or 10 mg / kg; n = 5-15 mice) on days 8, 12 and 15. Tumor growth will be measured.

[0276] The antibody-drug conjugates of 6-G23-F, 2-C8-A, 7-I1-B and 10-O18-A will be prepared using methods known in the literature. Some methods are disclosed in Examples 3-4 herein. One or more protein toxins (e.g., saporin toxins, Pseudomonas exotoxins and diphtheria toxins), radionuclides, anthracyclines, microtubule inhibitors, mitotic inhibitors, DNA damaging agents, nucleotide analogs, amino acid analogs, vitamin analogs are conjugated to 6-G23-F, 2-C8-A, 7-I1-B and 10-O18-A to generate 6-G23-F-ADC, 2-C8-A-ADC, 7-I1-B-ADC and 10-O18-A-ADC, respectively. Eight-week-old female athymic nude mice will be used in this study. NCI-H209 tumor cells will be grown to mid-log phase in RPMI containing 10% fetal calf serum (FCS). The cells were cultured in tissue culture flasks at 37 °C in 5% CO. 2 The mice were cultured in a humidified incubator with an atmosphere of 95% air. 5×10 cells in 50% Matrigel in a total volume of 0.2 ml were implanted subcutaneously on the right flank of the mice.6 NCI-H209 tumor cells. Eight days after inoculation, when the tumor reached approximately 150 mm 3 The mice were randomly divided into groups when the average tumor volume was . The mice were injected intraperitoneally with human IgG1-ADC (0.11 or 1 mg / kg; n = 5-15 mice) as a negative control or one or more of 6-G23-F-ADC, 2-C8-A-ADC, 7-I1-B-ADC or 10-O18-A-ADC (0.1 or 1 mg / kg; n = 5-15 mice) on days 8, 12 and 15. Tumor growth will be measured.

[0277] These results will demonstrate that the immunoglobulin-related compositions of the present technology can be used in methods of treating subjects suffering from DLL3-related cancers (e.g., small cell lung cancer, large cell neuroendocrine carcinoma, pulmonary neuroendocrine carcinoma, extrapulmonary neuroendocrine carcinoma, extrapulmonary neuroendocrine carcinoma, or melanoma). Equivalent

[0278] The technology of the present invention is not limited to the specific embodiments described in this application, and the embodiments are intended to be a single description of the individual aspects of the technology of the present invention. As will be clear to those skilled in the art, many modifications and changes can be made to the technology of the present invention without departing from the spirit and scope of the technology of the present invention. It will be clear to those skilled in the art from the foregoing description that, in addition to the methods and equipment listed herein, the functionally equivalent methods and equipment within the scope of the technology of the present invention. Such modifications and changes are intended to fall within the scope of the technology of the present invention. It should be understood that the technology of the present invention is not limited to specific methods, reagents, compounds, compositions or biological systems, and they can certainly change. It should also be understood that the terms used herein are only used for the purpose of describing specific embodiments and are not intended to be restrictive.

[0279] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[0280] It will be understood by those skilled in the art that for any and all purposes, particularly with respect to providing a written description, all ranges disclosed herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily identified as fully describing the same range and enabling the same range to be decomposed into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be easily decomposed into a lower third, a middle third, and an upper third, etc. As will be understood by those skilled in the art, all such as "up to", "at least", "greater than", "less than", etc., include the numbers and relate to the ranges that can subsequently be decomposed into sub-ranges as described above. Finally, as will be understood by those skilled in the art, the range includes each individual member. Therefore, for example, a group having 1-3 cells refers to a group having 1, 2, or 3 cells. Similarly, a group having 1-5 cells refers to a group having 1, 2, 3, 4, or 5 cells, etc.

[0281] All patents, patent applications, provisional applications, and publications mentioned or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

[0282] In summary, the present invention includes but is not limited to the following technical solutions: 1. An antibody or antigen-binding fragment thereof, comprising a heavy chain immunoglobulin variable domain (V H ) and light chain immunoglobulin variable domain (V L ),in (a) V H Contains V selected from the following H -CDR1 sequence, V H -CDR2 sequence and V H -CDR3 sequence: (i) SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively; (ii) SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15, respectively; (iii) SEQ ID NO:23, SEQ ID NO:24 and SEQ ID NO:25, respectively; and (iv) SEQ ID NO:33, SEQ ID NO:34 and SEQ ID NO:35, respectively; and / or (b) V L Contains V selected from the following L -CDR1 sequence, V L-CDR2 sequence and V L -CDR3 sequence: (i) SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively; (ii) SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, respectively; (iii) SEQ ID NO:28, SEQ ID NO:29 and SEQ ID NO:30, respectively; and (iv) SEQ ID NO: 38, SEQ ID NO: 39 and SEQ ID NO: 40, respectively. 2. An antibody or antigen-binding fragment thereof, comprising a heavy chain immunoglobulin variable domain (V H ) and light chain immunoglobulin variable domain (V L ),in: (a) V H comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 12, SEQ ID NO: 22, and SEQ ID NO: 32; and / or (b) V L Comprising an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:17, SEQ ID NO:27 and SEQ ID NO:37. 3. The antibody or antigen-binding fragment according to item 2, wherein said V H Amino acid sequence and the V L The amino acid sequence is selected from: SEQ ID NO: 2 and SEQ ID NO: 7 (7-I1-B), respectively; SEQ ID NO: 12 and SEQ ID NO: 17 (2-C8-A), respectively; SEQ ID NO: 22 and SEQ ID NO: 27 (10-018-A), respectively; and They are SEQ ID NO: 32 and SEQ ID NO: 37 (6-G23-F), respectively. 4. An antibody or an antigen-binding fragment thereof, comprising: (a) a light chain immunoglobulin variable domain sequence that is at least 95% identical to the light chain immunoglobulin variable domain sequence of any one of SEQ ID NO: 7, 17, 27 or 37; and / or (b) a heavy chain immunoglobulin variable domain sequence that is at least 95% identical to the heavy chain immunoglobulin variable domain sequence present in any one of SEQ ID NOs: 2, 12, 22 or 32. 5. The antibody or antigen-binding fragment according to any one of items 1 to 4, further comprising an Fc domain of an isotype selected from IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgM, IgD and IgE. 6. The antibody or antigen-binding fragment according to any one of items 1 to 4, wherein the antigen-binding fragment is selected from Fab, F(ab') 2 , Fab', scF v and F v . 7. The antibody according to any one of items 1 to 5, wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or a bispecific antibody. 8. The antibody or antigen-binding fragment of any one of items 1-7, wherein the antibody or antigen-binding fragment binds to an epitope present in a mammalian DLL3 polypeptide. 9. The antibody or antigen-binding fragment of item 8, wherein the epitope is a conformational epitope or a non-conformational epitope. 10. The antibody or antigen-binding fragment of item 8 or 9, wherein the mammalian DLL3 polypeptide has an amino acid sequence comprising amino acid residues 27-492 of SEQ ID NO:50 or SEQ ID NO:51. 11. A composition comprising an antibody or antigen-binding fragment according to any one of items 1 to 10 and a pharmaceutically acceptable carrier, wherein the antibody or antigen-binding fragment is optionally conjugated to an agent selected from the following: an isotope, a dye, a chromogen, a contrast agent, a drug, a toxin, a cytokine, an enzyme, an enzyme inhibitor, a hormone, a hormone antagonist, a growth factor, a radionuclide, a metal, a liposome, a nanoparticle, RNA, DNA or any combination thereof. 12. A recombinant nucleic acid sequence encoding the antibody or antigen-binding fragment according to any one of items 1 to 10. 13. A recombinant nucleic acid sequence, wherein the recombinant nucleic acid sequence is selected from the group consisting of: SEQ ID NO: 1, 6, 11, 16, 21, 26, 31 and 36. 14. A host cell or vector comprising the recombinant nucleic acid sequence according to item 12 or item 13. 15. A kit comprising the antibody or antigen-binding fragment according to any one of items 1 to 10 and instructions for use. 16. A kit according to item 15, wherein the antibody or antigen-binding fragment is coupled to at least one detectable label selected from a radioactive label, a fluorescent label and a chromogenic label. 17. A method for treating a DLL3-related cancer in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment according to any one of items 1-10, wherein the antibody or antigen-binding fragment is conjugated to at least one additional therapeutic agent. 18. A method according to claim 17, wherein the at least one additional therapeutic agent is selected from an isotope, a drug, a toxin, a cytokine, an enzyme, an enzyme inhibitor, a hormone, a hormone antagonist, a growth factor, a radionuclide, a metal, a liposome, a nanoparticle, RNA, DNA or any combination thereof. 19. The method of claim 17 or 18, wherein the DLL3-related cancer is small cell lung cancer, large cell neuroendocrine carcinoma, pulmonary neuroendocrine carcinoma, extrapulmonary neuroendocrine carcinoma, or melanoma. 20. A method for detecting the level of DLL3 protein in a biological sample, the method comprising: contacting the biological sample with the antibody or antigen-binding fragment according to any one of items 1 to 10, wherein the antibody or antigen-binding fragment is conjugated to a detectable label; and A signal generated by the detectable label is detected in the biological sample.

Claims

1. An anti-DLL-3 antibody or antigen-binding fragment thereof comprising a heavy chain immunoglobulin variable domain (V H ) and light chain immunoglobulin variable domain (V L ),in The V H V comprising SEQ ID NO: 33 H -CDR1 sequence, V of SEQ ID NO: 34 H -CDR2 sequence and V of SEQ ID NO:35 H -CDR3 sequence, and the V L The sequence comprises V of SEQ ID NO:38 L -CDR1 sequence, V of SEQ ID NO: 39 L -CDR2 sequence and V of SEQ ID NO:40 L -CDR3 sequence.

2. The anti-DLL-3 antibody or antigen-binding fragment thereof according to claim 1, wherein the V H The amino acid sequence is SEQ ID NO: 32 and the V L The amino acid sequence is SEQ ID NO:

37.

3. The anti-DLL-3 antibody or antigen-binding fragment thereof of claim 1, wherein the V L The sequence is at least 95% identical to the light chain immunoglobulin variable domain sequence of SEQ ID NO: 37, and the V H The sequence is at least 95% identical to the heavy chain immunoglobulin variable domain sequence of SEQ ID NO:

32.

4. The anti-DLL-3 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, further comprising an Fc domain of an isotype selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgM, IgD and IgE.

5. The anti-DLL-3 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein the antigen-binding fragment is selected from the group consisting of Fab, F(ab')2, Fab', scF v and F v Composed of groups.

6. The anti-DLL-3 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or a bispecific antibody.

7. The anti-DLL-3 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein the anti-DLL-3 antibody or antigen-binding fragment thereof binds to a conformational epitope or a non-conformational epitope present in a mammalian DLL3 polypeptide.

8. The anti-DLL-3 antibody or antigen-binding fragment thereof of claim 7, wherein the mammalian DLL3 polypeptide has an amino acid sequence comprising amino acid residues 27-492 of SEQ ID NO:50 or SEQ ID NO:

51.

9. A composition comprising the anti-DLL-3 antibody or antigen-binding fragment according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier.